+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Get PDF Full Texts from EurekaMag Chapter 46968

Chapter 46968 provides scholary research titles of which PDF Full Texts are available through EurekaMag.

Janssena, M.C.; Wollersheim, H.; Kraus, C.; Hildebrand, M.; Watson, H.R.; Thien, T., 2001:
Pharmacokinetics of oral iloprost in patients with Raynaud's phenomenon secondary to systemic sclerosis

Durnin, C.; Hind, I.D.; Ghani, S.P.; Yates, D.B.; Gegg, J., 2002:
Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in male and female subjects

Durnin, C.; Hind, I.D.; Ghani, S.P.; Yates, D.B.; Molz, K.H., 2002:
Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with moderate hepatic impairment

Durnin, C.; Hind, I.D.; Wickens, M.M.; Yates, D.B.; Molz, K.H., 2002:
Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with renal impairment

Durnin, C.; Hind, I.D.; Ghani, S.P.; Yates, D.B.; Cross, M., 2002:
Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in young and elderly subjects

Castañeda-Hernández, G.; Flores-Murrieta, F.J.; Granados-Soto, V.; Herrera-Abarca, A.; Pérez-Urizar, J.; Herrera, J.E.; Hong, E., 1996:
Pharmacokinetics of oral ranitidine in Mexicans

Gupta, E.; Vyas, V.; Ahmed, F.; Sinko, P.; Cook, T.; Rubin, E., 2001:
Pharmacokinetics of orally administered camptothecins

Figg, W.D.; Cole, K.A.; Reed, E.; Steinberg, S.M.; Piscitelli, S.C.; Davis, P.A.; Soltis, M.J.; Jacob, J.; Boudoulas, S.; Goldspiel, B., 1995 :
Pharmacokinetics of orally administered carboxyamido-triazole, an inhibitor of calcium-mediated signal transduction

Hale, V.G.; Bashaw, E.D., 1993:
Pharmacokinetics of oxaprozin

Moreno, L.; Serrano, J.M.; Guimerá, M.E.; Carceles, C.M., 1999:
Pharmacokinetics of oxytetracycline after intramuscular administration with lidocaine in sheep, comparison with a conventional formulation

Schrump, D.S.; Zhai, S.; Nguyen, D.M.; Weiser, T.S.; Fisher, B.A.; Terrill, R.E.; Flynn, B.M.; Duray, P.H.; Figg, W.D., 2002:
Pharmacokinetics of paclitaxel administered by hyperthermic retrograde isolated lung perfusion techniques

Huizing, M.T.; Giaccone, G.; van Warmerdam, L.J.; Rosing, H.; Bakker, P.J.; Vermorken, J.B.; Postmus, P.E.; van Zandwijk, N.; Koolen, M.G.; ten Bokkel Huinink, W.W.; van der Vijgh, W.J.; Bierhorst, F.J.; Lai, A.; Dalesio, O.; Pinedo, H.M.; Veenhof, C.H.; Beijnen, J.H., 1997:
Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre

Huizing, M.T.; Vermorken, J.B.; Rosing, H.; ten Bokkel Huinink, W.W.; Mandjes, I.; Pinedo, H.M.; Beijnen, J.H., 1995:
Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial

Fujita, H.; Okamoto, M.; Takao, A.; Mase, H.; Kojima, H., 1994:
Pharmacokinetics of paclitaxel in experimental animals. Part 1. Blood level

Fujita, H.; Okamoto, M.; Takao, A.; Mase, H.; Kojima, H., 1994:
Pharmacokinetics of paclitaxel in experimental animals. Part 2. Tissue distribution

Choi, J-Shik., 2003:
Pharmacokinetics of paclitaxel in rabbits with carbon tetrachloride-induced hepatic failure

Kwiatkowski, A.; Gawrońska-Szklarz, B.; Droździk, M.; Wójcicki, J., 1993:
Pharmacokinetics of paracetamol after removal of ovaries in rabbits

Schuitmaker, M.; Anderson, B.J.; Holford, N.H.; Woollard, G.A., 2000:
Pharmacokinetics of paracetamol in adults after cardiac surgery

Moreau, X.; L.Q.ay, L.; Granry, J.C.; Boishardy, N.; Delhumeau, A., 1993:
Pharmacokinetics of paracetamol in the cerebrospinal fluid in the elderly

Salpigides, G.; Pangalis, A.; Kouvelas, D.; Paradelis, A.G., 1995:
Pharmacokinetics of pefloxacin in human prostatic tissue

Bengtsson, B.; Jacobsson, S.O.; Luthman, J.; Franklin, A., 1997:
Pharmacokinetics of penicillin-G in ewes and cows in late pregnancy and in early lactation

Tang, G.H.; Jiang, G.H.; Zheng, L.F., 2001:
Pharmacokinetics of perlolyrine in rats by stable isotope dilution in conjunction with GC-MS

Ranheim, B.; Høiset, J.; Framstad, T.; Horsberg, T.E.; Skaare, J.U.; Søli, N.E., 1999:
Pharmacokinetics of pethidine in pigs following intravenous, intramuscular and subcutaneous administration

Daniel, W.A.; Syrek, M.; Haduch, A.; Wójcikowski, J., 1999:
Pharmacokinetics of phenothiazine neuroleptics after chronic coadministration of carbamazepine

D.V.au, E.J.; Pedersoli, W.; Cullison, R.; Baker, J., 1999:
Pharmacokinetics of phenylbutazone in plasma and milk of lactating dairy cows

Geary, R.S.; Yu, R.Z.; Levin, A.A., 2001 :
Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides

S.P.ter, J.V.; Lambrecht, L.J.; Gunderson, B.W.; Andersen, S.A.; Gallagher, S.C.; Swan, S.K., 2001:
Pharmacokinetics of pilocarpine in subjects with varying degrees of renal function

Robbins, P.K.; Tell, L.A.; Needham, M.L.; Craigmill, A.L., 2000:
Pharmacokinetics of piperacillan after intramuscular injection in red-tailed hawks (Buteo jamaicensis) and great horned owls (Bubo virginianus)

van der Werf, T.S.; Mulder, P.O.; Zijlstra, J.G.; Uges, D.R.; Stegeman, C.A., 1997:
Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH)

Kim, D.K.; Kim, H.T.; Cho, Y.B.; Kim, T.S.; Kim, K.H.; Hong, W.S., 1997:
Pharmacokinetics of platinum following the administration of cis-(glycolato-O,O')[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1, 3-dioxolane]platinum(II) in dogs

Mather, G.G.; Levy, R.H., 1996:
Pharmacokinetics of polypharmacy: prediction of drug interactions

Fang, Z.; Liu, X.; Xiao, Y.; Jiang, W., 2001:
Pharmacokinetics of pramiracetam in animals

Fourtillan, J.B.; Brisson, A.M.; Couet, W., 1993:
Pharmacokinetics of prazosin administered as gastro-intestinal-therapeutic-systems to 24 healthy volunteers

Kutrzeba, J.; Gawrońska-Szklarz, B.; Górnik, W.; Wójcicki, J., 1993:
Pharmacokinetics of procainamide in hyperlipidemia

Stanczyk, F.Z., 2001:
Pharmacokinetics of progesterone administered by the oral and parenteral routes

Strenkoski-Nix, L.C.; Ermer, J.; DeCleene, S.; Cevallos, W.; Mayer, P.R., 2000:
Pharmacokinetics of promethazine hydrochloride after administration of rectal suppositories and oral syrup to healthy subjects

Murat, I.; Billard, V.; Vernois, J.; Zaouter, M.; Marsol, P.; Souron, R.; Farinotti, R., 1996:
Pharmacokinetics of propofol after a single dose in children aged 1-3 years with minor burns. Comparison of three data analysis approaches

Nathan, N.; Debord, J.; Narcisse, F.; Dupuis, J.L.; Lagarde, M.; Benevent, D.; Lachatre, G.; Feiss, P., 1993:
Pharmacokinetics of propofol and its conjugates after continuous infusion in normal and in renal failure patients: a preliminary study

Lim, T.A., 1999:
Pharmacokinetics of propofol during conscious sedation using target-controlled infusion

Bailey, J.M.; Mora, C.T.; Shafer, S.L., 1996:
Pharmacokinetics of propofol in adult patients undergoing coronary revascularization. The Multicenter Study of Perioperative Ischemia Research Group

Kollöffel, W.J.; Weekers, L.E.; Goldhoorn, P.B., 1996:
Pharmacokinetics of propylene glycol after rectal administration

Roy, V.; Tekur, U.; Chopra, K., 1999:
Pharmacokinetics of pyrazinamide in children suffering from pulmonary tuberculosis

Payne, J.T.; McCaw, D.L.; Casteel, S.W.; Frazier, D.; Rogers, K.; Tompson, R.V., 1996:
Pharmacokinetics of pyropheophorbide-a-hexyl ether in the dog

Erlund, I.; Kosonen, T.; Alfthan, G.; Mäenpää, J.; Perttunen, K.; Kenraali, J.; Parantainen, J.; Aro, A., 2001:
Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers

Babalola, C.P.; Bolaji, O.O.; Ogunbona, F.A.; Sowunmi, A.; Walker, O., 1998:
Pharmacokinetics of quinine in African patients with acute falciparum malaria

Johnson, C.A.; Taylor, C.A.; Zimmerman, S.W.; Bridson, W.E.; Chevalier, P.; Pasquier, O.; Baybutt, R.I., 1998:
Pharmacokinetics of quinupristin-dalfopristin in continuous ambulatory peritoneal dialysis patients

Chevalier, P.; Rey, J.; Pasquier, O.; Leclerc, V.; Baguet, J.C.; Meyrier, A.; Harding, N.; Montay, G., 2000:
Pharmacokinetics of quinupristin/ dalfopristin in patients with severe chronic renal insufficiency

Mader, R.M.; Steger, G.G.; Rizovski, B.; Sieder, A.E.; Locker, G.; Gnant, M.F.; Jakesz, R.; Rainer, H., 1994:
Pharmacokinetics of rac-leucovorin vs [S]-leucovorin in patients with advanced gastrointestinal cancer

Lou, C.; Chen, Z-Nan.; Bian, H-Jie.; Li, J.; Zhou, S-Bo., 2002:
Pharmacokinetics of radioimmunotherapeutic agent of direct labeling mAb 188Re-HAb18

Knapp, F.F.; Kropp, J.; Franken, P.R.; Visser, F.C.; Sloof, G.W.; Eisenhut, M.; Yamamichi, Y.; Shirakami, Y.; Kusuoka, H.; Nishimura, T., 1996:
Pharmacokinetics of radioiodinated fatty acid myocardial imaging agents in animal models and human studies

Lai, J.; Quadri, S.M.; Borchardt, P.E.; Harris, L.; Wucher, R.; Askew, E.; Schweichel, L.; Vriesendorp, H.M., 1999:
Pharmacokinetics of radiolabeled polyclonal antiferritin in patients with Hodgkin's disease

Bergmann, J.F.; Laneury, J.P.; Duchene, P.; Fleishaker, J.C.; Houin, G.; Ségrestaa, J.M., 2001:
Pharmacokinetics of reboxetine in healthy, elderly volunteers

Björkman, S.; Shapiro, A.D.; Berntorp, E., 2001:
Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis

Thomsen, M.K.; Diness, V.; Nilsson, P.; Rasmussen, S.N.; Taylor, T.; Hedner, U., 1993:
Pharmacokinetics of recombinant factor VIIa in the rat--a comparison of bio-, immuno- and isotope assays

Wang, R.G.; Zhu, X.Z.; Song, W., 1999:
Pharmacokinetics of recombinant human granulocyte macrophage colony-stimulating factor in Macaca mulatta

Kim, J.; Zhi, J.; Satoh, H.; Koss-Twardy, S.G.; Passe, S.M.; Patel, I.H.; Pazdur, R., 1998:
Pharmacokinetics of recombinant human interferon-alpha 2a combined with 5-fluorouracil in patients with advanced colorectal carcinoma

Chiang, J.; Gloff, C.A.; Yoshizawa, C.N.; Williams, G.J., 1993:
Pharmacokinetics of recombinant human interferon-beta ser in healthy volunteers and its effect on serum neopterin

Aliab'eva, Z.Iu.; Matveev, M.Iu.; Evgrafov, V.Iu.; Domogatskiĭ, S.P., 1998:
Pharmacokinetics of recombinant pro-urokinase ocular dosage form

Blum, Z.; Iván, J.; Vass, K., 1997:
Pharmacokinetics of rectal absorption of amodiaquine in rabbits

Wu, Y.; Sitzmann, J.V., 1996:
Pharmacokinetics of regional angiotensin-II: a novel biologic response modifier

Stangier, J.; Su, C.A., 2001:
Pharmacokinetics of repeated oral doses of amlodipine and amlodipine plus telmisartan in healthy volunteers

Haunschild, J.; Steiner, K.; Faro, H.P.; Senekowitsch, R., 1995:
Pharmacokinetics of reshaped MAb 425 in three animal species

Allison, D.E.; Gourlay, S.G.; Koren, E.; Miller, R.M.; Fox, J.A., 2002:
Pharmacokinetics of rhuMAb CD18, a recombinant humanised monoclonal antibody fragment to CD18, in normal healthy human volunteers

Schilling, M.; Redaelli, C.; Friess, H.; Büchler, M.W., 1996:
Pharmacokinetics of rinse solutions at 4 degrees celsius

Izzedine, H.; Launay-Vacher, V.; Legrand, M.; Aymard, G.; Deray, G., 2001:
Pharmacokinetics of ritonavir and saquinavir in a haemodialysis patient

O'Kelly, B.; Fiset, P.; Meistelman, C.; Ecoffey, C., 1994:
Pharmacokinetics of rocuronium bromide in paediatric patients

Quitmann, J.; Kern, A.; Wulf, H., 2000:
Pharmacokinetics of ropivacaine during extradural anesthesia for total hip replacement

Habre, W.; Bergesio, R.; Johnson, C.; Hackett, P.; Joyce, D.; Sims, C., 2000:
Pharmacokinetics of ropivacaine following caudal analgesia in children

Pusuwan, P.; Chaiwatanarat, T.; Chaudakshetrin, P.; Virawat, N.; Pattaranutaporn, P.; Chansilpa, Y.; Suntornpong, N.; Tocharoenchai, C.; Buranapong, P.; Chanachai, R.; Suputtamongkol, Y.; Pleehachinda, R., 1996:
Pharmacokinetics of samarium-153-EDTMP in disseminated skeletal metastases

Acosta, E.P.; Zorrilla, C.; Van Dyke, R.; Bardeguez, A.; Smith, E.; Hughes, M.; Huang, S.; Pitt, J.; Watts, H.; Mofenson, L., 2001:
Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women

Favuzzi, A.M.; Mingrone, G.; Bertuzzi, A.; Salinari, S.; Gandolfi, A.; Greco, A.V., 2000:
Pharmacokinetics of sebacic acid in rats

Grzesiak, M.; Beszłej, J.A.; Kiejna, A., 2000:
Pharmacokinetics of second generation antidepressants

Nichols, D.J.; Muirhead, G.J.; Harness, J.A., 2002:
Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality

Shankar, S.M.; Jew, R.K.; Bickert, B.M.; Cavalieri, G.E.; Bell, L.M.; Lange, B.J., 1999:
Pharmacokinetics of single daily dose gentamicin in children with cancer

Stangier, J.; Su, C.A.; Brickl, R.; Franke, H., 2001:
Pharmacokinetics of single-dose telmisartan 120 mg given during and between hemodialysis in subjects with severe renal insufficiency: comparison with healthy volunteers

Yamatogi, Y.; Yoshinaga, H.; Oka, E.; Ohtahara, S.; Yamashita, S.; Furuno, K.; Gomita, Y., 1995:
Pharmacokinetics of slow-release preparations of sodium valproate

Liu, C.X.; Wei, G.L.; Xiao, S.H., 2001:
Pharmacokinetics of sodium bimetrondazole glycinate in mice and rats

Stein, G.; Sierakowski, B.; Grass, P.; Haufe, C.C.; Jansa, U.; Weidinger, G., 1994:
Pharmacokinetics of spirapril and spiraprilat in patients with chronic renal failure

Meredith, P.A.; Grass, P.; Guitard, C.; Elliott, H.L., 1994:
Pharmacokinetics of spirapril in renal impairment

Arndt, D.; Zeisig, R.; Fichtner, I.; Teppke, A.D.; Fahr, A., 2000:
Pharmacokinetics of sterically stabilized hexadecylphosphocholine liposomes versus conventional liposomes and free hexadecylphosphocholine in tumor-free and human breast carcinoma bearing mice

Hadi, A.A.; Wasfi, I.A.; Bashir, A.K.; Gadir, F.A., 1999:
Pharmacokinetics of streptomycin in camels

Hudson, R.J.; Henderson, B.T.; Thomson, I.R.; Moon, M.; Peterson, M.D., 2001:
Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery

Barthel, G., 1993:
Pharmacokinetics of sulfamerazine after a single intravenous dose in healthy calves and calves with diarrhea of different severity with consideration of the influence of an existing kidney function restriction

Luo, W.X.; Zhang, Y.D.; Shen, J.P.; Ding, Y.; Huang, D.K.; Luo, J.P.; Qiu, J.; Jiang, Z.H.; Peng, J.H.; Sheng, L.S., 2001:
Pharmacokinetics of sustained-release capsule of 5-isosorbide mononitrate in 20 healthy Chinese young men

Undre, N.A.; Meiser, B.M.; Uberfuhr, P.; Reichart, B.; Stevenson, P.; Schäfer, A.; Möller, A., 1998:
Pharmacokinetics of tacrolimus (FK506) in primary orthotopic heart transplant patients

Thielke, J.; Martin, J.; Weber, F.L.; Schroeder, T.J.; Goretsky, S.; Hanto, D.W., 1998:
Pharmacokinetics of tacrolimus and cyclosporine in short-bowel syndrome

Koiso, K.; Akaza, H.; Kikuchi, K.; Aoyagi, K.; Ohba, S.; Miyazaki, M.; Ito, M.; Sueyoshi, T.; Matsushima, H.; Kamimura, H.; Watanabe, T.; Higuchi, S., 1996:
Pharmacokinetics of tamsulosin hydrochloride in patients with renal impairment: effects of alpha 1-acid glycoprotein

Alet, P.; Lortholary, O.; Fauvelle, F.; Tod, M.; Genereau, T.; Louchahi, M.; Leon, A.; Guillevin, Lïc.; Petitjean, O., 2002:
Pharmacokinetics of teicoplanin during plasma exchange

Püchler, K.; Eckl, K.M.; Fritsche, L.; Renneisen, K.; Neumayer, H.H.; Sierakowski, B.; Lavrijssen, A.T.; Thomsen, T.; Roots, I., 1998:
Pharmacokinetics of temocapril and temocaprilat after 14 once daily oral doses of temocapril in hypertensive patients with varying degrees of renal impairment

Hnatowich, D.J.; Mardirossian, G.; Rusckowski, M.; Roy, S.; Bushe, H.; Griffin, T.W.; Brill, A.B., 1993:
Pharmacokinetics of the FO23C5 anti-CEA antibody fragment labelled with 99Tcm and 111In: a comparison in patients

Qian, M.; Wang, X.; Shanmuganathan, K.; Chu, C.K.; Gallo, J.M., 1994:
Pharmacokinetics of the anticancer agent 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine in rats

O'Dwyer, P.J.; Szarka, C.; Brennan, J.M.; Laub, P.B.; Gallo, J.M., 2001:
Pharmacokinetics of the chemopreventive agent oltipraz and of its metabolite M3 in human subjects after a single oral dose

Swart, P.J.; de Zeeuw, R.A., 1993:
Pharmacokinetics of the dopamine D2 agonist S(-)-2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin in freely moving rats

Zhong, W.Z.; Williams, M.G.; Schuette, M.R.; Vandegiessen, T.L.; Jones, B.W., 1996:
Pharmacokinetics of the individual enantiomers of cis-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]-benzamide monohydrochloride (U-54494A) in the dog

Stampfli, H.F.; Person, C.R.; Huang, S.M.; Quon, C.Y., 1994:
Pharmacokinetics of the inodilator XB513 in mice, rats, guinea pigs, rabbits, dogs, and monkeys

Gidal, B.E., 2001:
Pharmacokinetics of the new antiepileptic drugs

Burke, M.J.; Harvey, A.T.; Preskorn, S.H., 1996:
Pharmacokinetics of the newer antidepressants

Kuhl, H., 1998:
Pharmacokinetics of the newer progestogens and the controversy about gestodene

Hussein, Z.; Beerahee, M.; Grover, R.; Jordan, B.; Jeffs, R.; Donaldson, J.; Zaccardelli, D.; Colice, G.; Guntupalli, K.; Watson, D.; Vincent, J.L., 1999:
Pharmacokinetics of the nitric oxide synthase inhibitor L-NG-methylarginine hydrochloride in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group

Boĭko, S.S.; Vitskova, G.Iu.; Zherdev, V.P., 1998:
Pharmacokinetics of the nootropic drugs

Simons, F.E.; Gu, X.; Watson, W.T.; Simons, K.J., 1996:
Pharmacokinetics of the orally administered decongestants pseudoephedrine and phenylpropanolamine in children

Jovanović, D.; Randelović, S.; Joksović, D.; Todorović, V., 1993:
Pharmacokinetics of the oxime, HI-6, in patients with acute organophosphorus insecticide poisoning

Sugarbaker, P.H.; Stuart, O.A.; Vidal-Jove, J.; Pessagno, A.M.; DeBruijn, E.A., 1996:
Pharmacokinetics of the peritoneal-plasma barrier after systemic mitomycin C administration

Bading, J.R.; Shahinian, A.H.; Bathija, P.; Conti, P.S., 2000:
Pharmacokinetics of the thymidine analog 2'-fluoro-5-[(14)C]-methyl-1-beta-D-arabinofuranosyluracil ([(14)C]FMAU) in rat prostate tumor cells

Ahn, H.W.; Shin, W.G.; Park, K.J.; Suh, O.K.; Choi, J.H., 2000:
Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea

Witschital, K.; Fuchs, W.S.; Heese, U.; von Nieciecki, A.; Laicher, A., 1998:
Pharmacokinetics of theophylline in sustained-release formulation in young asthmatics

Cao, W.; Zhuo, H.T.; Chen, G.; Ling, S.S., 1999:
Pharmacokinetics of theophylline metabolites in 8 Chinese patients

Daniel, W.A.; Syrek, M.; Mach, A.; Wójcikowski, J.; Boksa, J., 1998:
Pharmacokinetics of thioridazine and its metabolites in blood plasma and the brain of rats after acute and chronic treatment

VanDenBerg, C.M.; Kazmi, Y.; Stewart, J.; Weidler, D.J.; Tenjarla, S.N.; Ward, E.S.; Jann, M.W., 2000:
Pharmacokinetics of three formulations of ondansetron hydrochloride in healthy volunteers: 24-mg oral tablet, rectal suppository, and i.v. infusion

Reitberg, D., 2001:
Pharmacokinetics of topical antifungal formulations

Green, L.C.; Callegan, M.C.; Engel, L.S.; Shimomura, Y.; Jasheway, D.W.; O'Callaghan, R.J.; Hill, J.M., 1996:
Pharmacokinetics of topically applied ciprofloxacin in rabbit tears

Zhang, J.; Xie, L.; Chen, Z.; Zhang, Q., 2002:
Pharmacokinetics of topically applied fluconazole in the rabbit eye

Zhang, J.J.; Xie, L.K.; Zhao, N.M.; Chen, Z.J.; Xu, Y., 2001:
Pharmacokinetics of topically applied in-situ-forming gels of fluconazole in rabbit eyes

Huang, X.; Ren, P.; Wen, A-Dong.; Wang, L-Li.; Zhang, L.; Gao, F., 2002:
Pharmacokinetics of traditional Chinese syndrome and recipe: a hypothesis and its verification (I)

Paut, O.; Camboulives, J.; Viard, L.; Lemoing, J.P.; Levron, J.C., 2000:
Pharmacokinetics of transdermal fentanyl in the peri-operative period in young children

DeVane, C.Lindsay.; Boulton, D.W.; Miller, L.F.; Miller, R.L., 2001:
Pharmacokinetics of trazodone and its major metabolite m-chlorophenylpiperazine in plasma and brain of rats

Santré, C.; Leroy, O.; Simon, M.; Georges, H.; Guery, B.; Beuscart, C.; Beaucaire, G., 1993:
Pharmacokinetics of vancomycin during continuous hemodiafiltration

Ginovart Galiana, G.; Mangues Bafalluy, M.A.; Demestre Guasch, X.; Farré Riba, R.; Lopes Santos, A.P.; Altirriba Valls, O., 1996:
Pharmacokinetics of vancomycin in neonates of postconceptional age less than or equal to 32 weeks

Rojas, A.; Hodgkiss, R.J.; Stratford, M.R.; Dennis, M.F.; Johns, H., 1993:
Pharmacokinetics of varying doses of nicotinamide and tumour radiosensitisation with carbogen and nicotinamide: clinical considerations

Xue, F.S.; Liao, X.; Tong, S.Y.; Liu, J.H.; Li, L.; Zou, Q.; Luo, L.K., 1998:
Pharmacokinetics of vecuronium during acute isovolaemic haemodilution

Bhatti, M.M.; Lewanczuk, R.Z.; Pasutto, F.M.; Foster, R.T., 1995:
Pharmacokinetics of verapamil and norverapamil enantiomers after administration of immediate and controlled-release formulations to humans:evidence suggesting input-rate determined stereoselectivity

Solans, C.; Aramayona, J.J.; Bregante, M.A.; Fraile, L.J.; Rueda, S.; Garcia, M.A., 2001:
Pharmacokinetics of verapamil in lactating rabbits. Prediction of verapamil distribution into rabbit milk

Menache, D., 1999:
Pharmacokinetics of von Willebrand factor and factor VIII coagulant activity in patients with von Willebrand disease type 3 and type 2

Stokol, T.; Trepanier, L.; Parry, B.W.; Finnin, B.C., 1997:
Pharmacokinetics of von Willebrand factor and factor VIII in canine von Willebrand disease and haemophilia A

Menache, D.; Aronson, D.L.; Darr, F.; Montgomery, R.R.; Gill, J.C.; Kessler, C.M.; Lusher, J.M.; Phatak, P.D.; Shapiro, A.D.; Thompson, A.R.; White, G.C., 1996:
Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Cooperative Study Groups

Tokairin, Y.; Maruyama, M.; Baba, H.; Yoshida, T.; Kure, N.; Nagahama, T.; Ebuchi, M., 2001:
Pharmacokinetics of "subselective" arterial infusion chemotherapy

Howard, C.E.; Capers, C.C.; Bess, D.T.; Anderson, R.J., 1994:
Pharmacokinetics services in Department of Veterans Affairs medical centers

Nguyen, D.; Emond, C.; Leclerc, Y.; Sherman, I.; Dube, P., 2003:
Pharmacokinetics studies and toxicity profile of raltitrexed used by intraperitoneal route in normothermia in a pig model

Tsukagoshi, S., 2000:
Pharmacokinetics studies of nafamostat mesilate (FUT), a synthetic protease inhibitor, which has been used for the treatments of DIC and acute pancreatitis, and as an anticoagulant in extracorporeal circulation

Han, G.R.; Cai, G.F., 1993:
Pharmacokinetics study of intraperitoneal cisplatin in ovarian carcinoma

Boxenbaum, H.; Tannenbaum, S.; Mayersohn, M.; Oleson, F., 2000:
Pharmacokinetics tricks and traps: drug dosage adjustment in renal failure

Boxenbaum, H., 2000:
Pharmacokinetics tricks and traps: flip-flop models

Smith, B.E., 1995:
Pharmacokinetics without calculus--an introduction

Barbhaiya, R.H.; Dandekar, K.A.; Greene, D.S., 1996:
Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in humans

Shukla, U.A.; Marathe, P.H.; Pittman, K.A.; Barbhaiya, R.H., 1993:
Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in the dog

Fisher, J.; Johnston, A.M.; Holland, T.K.; McCallum, J.; Pescador, R.; Mantovani, M.; Prino, G., 1993:
Pharmacokinetics, absorption, distribution and disposition of [125I]-defibrotide following intravenous or oral administration in the rat

Fisher, J.; Holland, T.K.; Pescador, R.; Porta, R.; Ferro, L., 1997:
Pharmacokinetics, absorption, distribution and disposition of [125I]-oligotide following intravenous or oral administration in the rat

Sharir, M.; Pierce, W.M.; Chen, D.; Zimmerman, T.J., 1994:
Pharmacokinetics, acid-base balance and intraocular pressure effects of ethyloxaloylazolamide--a novel topically active carbonic anhydrase inhibitor

Murilla, G.A.; Mdachi, R.E.; Karanja, W.M., 1996:
Pharmacokinetics, bioavailability and tissue residues of [14C]isometamidium in non-infected and Trypanosoma congolense-infected Boran cattle

Temsamani, J.; Tang, J.Y.; Padmapriya, A.; Kubert, M.; Agrawal, S., 1993:
Pharmacokinetics, biodistribution, and stability of capped oligodeoxynucleotide phosphorothioates in mice

Waldmeier, F.; Flesch, G.; Müller, P.; Winkler, T.; Kriemler, H.P.; Bühlmayer, P.; D.G.sparo, M., 1997:
Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose

Schwartz, S.; Clare, R.; Devereux, K.; Sheung, C.F., 1998:
Pharmacokinetics, disposition and metabolism of 546C88 (L-NG-methylarginine hydrochloride) in rat and dog

Yasoshima, K.; Kuwabara, T.; Fuse, E.; Kuramitu, T.; Kurata, N.; Nishiie, H.; Oishi, T.; Kobayashi, H.; Kobayashi, S., 2001 :
Pharmacokinetics, distribution, metabolism and excretion of

Juweid, M.E.; Stadtmauer, E.; Hajjar, G.; Sharkey, R.M.; Suleiman, S.; Luger, S.; Swayne, L.C.; Alavi, A.; Goldenberg, D.M., 1999:
Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma

Dobrkovska, A.; Krzensk, U.; Chediak, J.R., 1999:
Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease

Knibbe, C.A.; Voortman, H.J.; Aarts, L.P.; Kuks, P.F.; Lange, R.; Langemeijer, H.J.; Danhof, M., 1999:
Pharmacokinetics, induction of anaesthesia and safety characteristics of propofol 6% SAZN vs propofol 1% SAZN and Diprivan-10 after bolus injection

Radulovic, L.L.; Bockbrader, H.N.; Chang, T., 1993:
Pharmacokinetics, mass balance, and induction potential of a novel GABA uptake inhibitor, CI-966 HCl, in laboratory animals

Sutton, B.M.; Reeves, N.J.; Naylor, M.A.; Fielden, E.M.; Cole, S.; Adams, G.E.; Stratford, I.J., 1994:
Pharmacokinetics, metabolism and distribution of 1,2-dihydro-8-(4-methylpiperazinyl)-4-phenylimidazo [1,2-A] pyrido [3,2-E] pyrazine-5-oxide in C3H mice

Benichou, C., 1996:
Pharmacokinetics, metabolism and pharmacovigilance

Cummings, J.; Langdon, S.P.; Ritchie, A.A.; Burns, D.J.; Mackay, J.; Stockman, P.; Leonard, R.C.; Miller, W.R., 1996:
Pharmacokinetics, metabolism and tumour disposition of 8-chloroadenosine 3',5'-monophosphate in breast cancer patients and xenograft bearing mice

Slatter, J.G.; Schaaf, L.J.; Sams, J.P.; Feenstra, K.L.; Johnson, M.G.; Bombardt, P.A.; Cathcart, K.S.; Verburg, M.T.; Pearson, L.K.; Compton, L.D.; Miller, L.L.; Baker, D.S.; Pesheck, C.V.; Lord, R.S., 2000:
Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients

Slatter, J.G.; Stalker, D.J.; Feenstra, K.L.; Welshman, I.R.; Bruss, J.B.; Sams, J.P.; Johnson, M.G.; Sanders, P.E.; Hauer, M.J.; Fagerness, P.E.; Stryd, R.P.; Peng, G.W.; Shobe, E.M., 2001:
Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects

Cummings, J.; MacLellan, A.J.; Jones, D.A.; Langdon, S.P.; Rozengurt, E.; Ritchie, A.A.; Smyth, J.F., 1995:
Pharmacokinetics, metabolism, tissue and tumour distribution of the neuropeptide growth factor antagonist [Arg6, D-Trp7,9, NmePhe8]- substance P(6-11) in nude mice bearing the H69 small-cell lung cancer xenograft

Frick, L.W.; S.J.hn, L.; Taylor, L.C.; Painter, G.R.; Furman, P.A.; Liotta, D.C.; Furfine, E.S.; Nelson, D.J., 1993:
Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus

Torlone, E.; Fanelli, C.; Rambotti, A.M.; Kassi, G.; Modarelli, F.; D.V.ncenzo, A.; Epifano, L.; Ciofetta, M.; Pampanelli, S.; Brunetti, P., 1994:
Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDM

Strange, P.; Schwartz, S.L.; Graf, R.J.; Polvino, W.; Weston, I.; Marbury, T.C.; Huang, W.C.; Goldberg, R.B., 2001:
Pharmacokinetics, pharmacodynamics, and dose-response relationship of repaglinide in type 2 diabetes

Drover, D.; Lemmens, H.; Naidu, S.; Cevallos, W.; Darwish, M.; Stanski, D., 2001:
Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem

Russell, T.; Stoltz, M.; Weir, S., 1999:
Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers

Elbrønd, B.; Jakobsen, G.; Larsen, Søren.; Agersø, H.; Jensen, L.Bjerring.; Rolan, P.; Sturis, J.; Hatorp, V.; Zdravkovic, M., 2002 :
Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects

Tabrizi-Fard, M.A.; Fung, H.L., 1994:
Pharmacokinetics, plasma protein binding and urinary excretion of N omega-nitro-L-arginine in rats

Luzzati, R.; D.P.rri, G.; Fendt, D.; Ramarli, D.; Broccali, G.; Concia, E., 1998:
Pharmacokinetics, safety and anti-human immunodeficiency virus (HIV) activity of hydroxyurea in combination with didanosine

Swan, S.K.; Baker, J.F.; Free, R.; Tucker, R.M.; Barron, B.; Barr, R.; Seltzer, S.; Gazelle, G.S.; Maravilla, K.R.; Barr, W.; Stevens, G.R.; Lambrecht, L.J.; Pierro, J.A., 1999:
Pharmacokinetics, safety, and tolerability of gadoversetamide injection (OptiMARK) in subjects with central nervous system or liver pathology and varying degrees of renal function

Kim, S.H.; Moon, Y.J.; Ryu, C.K.; Lee, M.G., 2001:
Pharmacokinetics, stability, and blood partition of 7-anilino-5,8-isoquinolinedione, a new isoquinonlinedione derivative

Shim, H.J.; Lee, E.J.; Kim, S.H.; Kim, S.H.; Yoo, M.; Kwon, J.W.; Kim, W.B.; Lee, H.S.; Lee, M.G., 2002:
Pharmacokinetics, stability, and blood partition of DA-8159, a new phosphodiesterase V inhibitor

Plakas, S.M.; el Said, K.R.; Bencsath, F.A.; Musser, S.M.; Hayton, W.L., 1998:
Pharmacokinetics, tissue distribution and metabolism of acriflavine and proflavine in the channel catfish (Ictalurus punctatus)

Cho, Y.B.; Kim, K.H.; Kim, D.K., 1995:
Pharmacokinetics, tissue distribution, and excretion of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3- dioxolane]platinum(II) in dogs

Osaka, G.; Carey, K.; Cuthbertson, A.; Godowski, P.; Patapoff, T.; Ryan, A.; Gadek, T.; Mordenti, J., 1996:
Pharmacokinetics, tissue distribution, and expression efficiency of plasmid [33P]DNA following intravenous administration of DNA/cationic lipid complexes in mice: use of a novel radionuclide approach

Evans, J.L.; Heymann, C.J.; Goldfine, I.D.; Gavin, L.A., 2002:
Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled-release formulation of alpha-lipoic acid

Gokhale, P.C.; Zhang, C.; Newsome, J.T.; Pei, J.; Ahmad, I.; Rahman, A.; Dritschilo, A.; Kasid, U.N., 2002:
Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome

Kaur, G.; Chaudhary, R.K.; Srivastava, A.K., 2001:
Pharmacokinetics, urinary excretion and dosage regimen of diminazene in crossbred calves

Chohfi, M.; Langlais, F.; Fourastier, J.; Minet, J.; Thomazeau, H.; Cormier, M., 1998:
Pharmacokinetics, uses, and limitations of vancomycin-loaded bone cement

Benet, L.Z.; Zech, K., 1994:
Pharmacokinetics--a relevant factor for the choice of a drug?

Balant, L.P.; Gex-Fabry, M., 1993:
Pharmacokinetics/pharmacodynamics during phase II and III studies: population kinetics and the kinetic screen

Chaikin, P.; Rhodes, G.R.; Bruno, R.; Rohatagi, S.; Natarajan, C., 2001:
Pharmacokinetics/pharmacodynamics in drug development: an industrial perspective

L.G.ellec, C.; Roiron, R.; Vaillant, L., 2000:
Pharmacokinetics: elementary notions

Munk, B., 2001:
Pharmacokinetics: what is it about?

Friedman, A.N., 2002:
Pharmacologic B-vitamin therapy for hyperhomocysteinemia in dialysis patients: has the time come?

Beauchamp; Bergeron, 2000:
Pharmacologic Basis for the Treatment of Pyelonephritis

Schuh, L.M.; Schuh, K.J.; Henningfield, J.E., 1996:
Pharmacologic Determinants of Tobacco Dependence

Dalton, 2000:
Pharmacologic Treatment of Cancer: New Developments

Moser, M., 1995:
Pharmacologic Treatment of Hypertension in the Elderly

Giles, T.D., 2001:
Pharmacologic Update - ACE/Kininase II Inhibitors in Older Patients With Cardiovascular Diseases: "HOPE" Springs Eternal

Giles, T.D., 2001:
Pharmacologic Update - Beta Blockers in Treatment of Heart Failure and Hypertension in Diabetes: Ugly Misconceptions Slain by Beautiful Clinical Data

Webster, P.J.; Raper, R.F.; Ross, D.E.; Edwards, A.C.; Choong, C.Y., 1993:
Pharmacologic abolition of severe mitral regurgitation associated with dynamic left ventricular outflow tract obstruction after mitral valve repair: confirmation by transesophageal echocardiography

Ferrari, P.; Frey, F.J., 2000:
Pharmacologic action of diuretics in the kidney

Joseph, G.; Zhao, Y.; Klaus, W., 1995:
Pharmacologic action profile of crataegus extract in comparison to epinephrine, amirinone, milrinone and digoxin in the isolated perfused guinea pig heart

Lemière, S.; Bruley Des Varannes, S., 1999:
Pharmacologic actions and therapeutic importance of botulinum toxin in digestive diseases

Kikukawa, H.; Yoshida, M.; Wada, Y.; Nishi, K.; Ueda, S., 1998:
Pharmacologic actions of temiverine (p-INN) and its active metabolite, RCC-36, on isolated human urinary bladder muscle

Jackson, W.T.; Froelich, L.L.; Boyd, R.J.; Schrementi, J.P.; Saussy, D.L.; Schultz, R.M.; Sawyer, J.S.; Sofia, M.J.; Herron, D.K.; Goodson, T.; Snyder, D.W.; Pechous, P.A.; Spaethe, S.M.; Roman, C.R.; Fleisch, J.H., 1998:
Pharmacologic actions of the second-generation leukotriene B4 receptor antagonist LY293111: in vitro studies

García González, M.; González Camacho, S.M.; Pazos Sanou, L., 1997:
Pharmacologic activity of the aqueous wood extract from Quassia amara (Simarubaceae) on albino rats and mice

Albertson, T.E.; Marelich, G.P., 1999:
Pharmacologic adjuncts to mechanical ventilation in acute respiratory distress syndrome

de Haan, P., 2001:
Pharmacologic adjuncts to protect the spinal cord during transient ischemia

Dionne, R.A., 2002:
Pharmacologic advances in orofacial pain: from molecules to medicine

Keith, S.J., 1997:
Pharmacologic advances in the treatment of schizophrenia

Preston, R.R.; Naseer, S.; Newhouse, H.K.; dePuey, E.G., 1992:
Pharmacologic agents aid perfusion imaging

Takeuchi, M.; Yokoyama, M., 1994:
Pharmacologic agents for heart failure in myocardial infarction

McElroy, S.L.; Keck, P.E., 2000:
Pharmacologic agents for the treatment of acute bipolar mania

Haller, C.; Schwartz, J.B., 2002:
Pharmacologic agents for weight reduction

Abdulla, R., 1997:
Pharmacologic agents inducing electrocardiac conduction delays

Rosen, G.H., 1995:
Pharmacologic agents used for nutritional disorders of HIV/AIDS

Helge, T.D.; Denelsky, G.Y., 2000:
Pharmacologic aids to smoking cessation

Dicarlo, J.B.; McCall, C.O., 2001:
Pharmacologic alternatives for severe atopic dermatitis

Chiari, A.; Lorber, C.; Kainz, C.; Brinkmann, H.; Krenn, C.; Klimscha, W., 1997:
Pharmacologic alternatives to classic regional anesthesia in obstetrics

Popper, C.W., 2000:
Pharmacologic alternatives to psychostimulants for the treatment of attention-deficit/hyperactivity disorder

Molodavkin, G.M.; Burlakova, E.B.; Cherniavskaia, L.I.; Voronina, T.A.; Khorseva, N.I.; Seredenii, S.B., 1996:
Pharmacologic analysis of phenazepam and flunitrazepam activity when administered in extremely low doses

Gromov, L.A.; Portniagina, V.A.; Sereda, P.I.; Bobkova, L.S., 1993:
Pharmacologic analysis of the free radical mechanism of poisoning-induced memory disorders

Vasin, M.V.; Ushakov, I.B.; Semenova, L.A.; Kovtun, V.Iu., 2001:
Pharmacologic analysis of the radiation-protecting effect of indraline

Bol'shakov, K.B.; Buldakova, S.L., 2000:
Pharmacologic analysis of the subunit composition of AMPA-receptors in the hippocampal neurons

Sumano López, H.; Hoyas Sepúlveda, M.L.; Brumbaugh, G.W., 1999:
Pharmacologic and alternative therapies for the horse with chronic laminitis

Albengres, E., 2000:
Pharmacologic and biologic basis of drug allergies

Decker, G.M., 2000:
Pharmacologic and biologic therapies in cancer care

Decker, G.M., 2002:
Pharmacologic and biologic therapies in cancer care: Part II

Iwata, H., 1993:
Pharmacologic and clinical aspects of intraarticular injection of hyaluronate

May, B.; Greving, I., 1996:
Pharmacologic and clinical differentiation of prokinetic drugs

García-Zaragozá, E.; Moreno, L.; Esplugues, J.V., 2001:
Pharmacologic and clinical interest of serotonergic receptors of the gastrointestinal tract

Giles, T.D., 1997:
Pharmacologic and clinical perspectives on mibefradil: a new T-channel selective calcium antagonist: introduction

Winterhoff, H.; Butterweck, V.; Jarry, H.; Wuttke, W., 2002:
Pharmacologic and clinical studies using Cimicifuga racemosa in climacteric complaints

Ziff, H.; Kominars, K.; Wasserman, C.; Soucar, E., 1993:
Pharmacologic and cognitive-behavioral treatment for bulimia nervosa

Escolar, D.M.; Scacheri, C.G., 2002:
Pharmacologic and genetic therapy for childhood muscular dystrophies

Levy, J.H., 1993:
Pharmacologic and mechanical methods of discontinuing extracorporeal circulation in patients with heart failure

Bodnár, J., 1998:
Pharmacologic and non-pharmacologic therapy of ventricular tachyarrhythmias

Sung, C.; Parry, T.J.; Riccobene, T.A.; Mahoney, A.; Roschke, V.; Murray, J.; Gu, M.Li.; Glenn, J.K.; Caputo, F.; Farman, C.; Odenheimer, D.J., 2002:
Pharmacologic and pharmacokinetic profile of repifermin (KGF-2) in monkeys and comparative pharmacokinetics in humans

Yoshimura, N.; Smith, C.P.; Chancellor, M.B.; de Groat, W.C., 2001:
Pharmacologic and potential biologic interventions to restore bladder function after spinal cord injury

Ruffolo, R.R.; Nichols, A.J.; Stadel, J.M.; Hieble, J.P., 1993:
Pharmacologic and therapeutic applications of alpha 2-adrenoceptor subtypes

Triggle, D.J., 1996:
Pharmacologic and therapeutic differences among calcium channel antagonists: profile of mibefradil, a new calcium antagonist

Kohút, A.; Kalina, I., 1999:
Pharmacologic and toxicologic results in genetic polymorphisms (review)

Ryan, J.M., 2001:
Pharmacologic approach to aggression in neuropsychiatric disorders

Senard, J.M.; Montastruc, J.L., 1998:
Pharmacologic approach to autonomic failure

Cesselin, F., 1998:
Pharmacologic approach to chronic pain. Recent findings

Awad, K.; Ali, P.; Frishman, W.H.; Tejani, N., 2001:
Pharmacologic approaches for the management of systemic hypertension in pregnancy

Jimerson, D.C.; Herzog, D.B.; Brotman, A.W., 1993:
Pharmacologic approaches in the treatment of eating disorders

Dellasega, C.; Keiser, C.L., 1997:
Pharmacologic approaches to chronic pain in the older adult

Shearer, S.B., 1977:
Pharmacologic approaches to contraception in men

Weiss, J.F., 1998:
Pharmacologic approaches to protection against radiation-induced lethality and other damage

Freemark, M., 2003:
Pharmacologic approaches to the prevention of type 2 diabetes in high risk pediatric patients

Calkins, H., 1999 :
Pharmacologic approaches to therapy for vasovagal syncope

Kochs, E.; Blobner, M., 2000:
Pharmacologic aspects of endotracheal intubation

Hübner, R.; Fuchs, W., 2001:
Pharmacologic basics: the effect of AT1 receptor antagonists

Antonaccio, M.J.; Gomoll, A., 1993:
Pharmacologic basis of the antiarrhythmic and hemodynamic effects of sotalol

Zunino, F.; Perego, P., 1999:
Pharmacologic basis of the effectiveness of topotecan in the treatment of ovarian carcinoma

Olivieri, A.; Poloni, A.; Montanari, M.; Cantori, I.; Corvatta, L.; Masia, M.C.; Curzi, L.; Mancini, S.; Leoni, P., 1997:
Pharmacologic bone marrow purging: is there any place for etoposide? In vitro comparison with mafosfamide

Steele, A.C.; Kohli, N.; Mallipeddi, P.; Karram, M., 1999:
Pharmacologic causes of female incontinence

Burkman, R.T., 2001:
Pharmacologic characteristics of progestins used for contraception and hormone replacement therapy, including new transdermal technologies

Percy, W.H.; Miller, A.J.; Brunz, J.T., 1998:
Pharmacologic characteristics of rabbit esophageal muscularis mucosae in vitro

Dubois, E.A.; Somsen, G.A.; van den Bos, J.C.; Janssen, A.G.; Boer, G.J.; Batink, H.D.; van Royen, E.A.; Pfaffendorf, M.; van Zwieten, P.A., 1996:
Pharmacologic characterization in vitro and in vivo of iodine 123-labeled derivatives of the beta-adrenoceptor antagonist CGP12177, designed for the imaging of cardiac beta-receptors

Gibbons, J.A.; Hancock, A.A.; Vitt, C.R.; Knepper, S.; Buckner, S.A.; Brune, M.E.; Milicic, I.; Kerwin, J.F.; Richter, L.S.; Taylor, E.W.; Spear, K.L.; Zuckermann, R.N.; Spellmeyer, D.C.; Braeckman, R.A.; Moos, W.H., 1996:
Pharmacologic characterization of CHIR 2279, an N-substituted glycine peptoid with high-affinity binding for alpha 1-adrenoceptors

Lemoine, H.; Worth, H.; Reinhardt, D., 1993:
Pharmacologic characterization of formoterol in comparison with isoprenaline, fenoterol and salbutamol in tracheal muscle strips and lung membranes of the guinea pig

Su, T.P., 1993:
Pharmacologic characterizations of sigma receptors

Payton, R.G.; Gardner, R.; Reynolds, D., 1997:
Pharmacologic considerations and management of common endocrine disorders in women

Ireland, R.R., 2002:
Pharmacologic considerations for serotonin reuptake inhibitor use by aviators

Nielson, C., 1994:
Pharmacologic considerations in critical care of the elderly

Naylor, G.D.; Fredericks, M.R., 1996:
Pharmacologic considerations in the dental management of the patient with disorders of the renal system

Walinsky, M.D., 1993:
Pharmacologic considerations in the geriatric patient

Koerner, K.R.; Taylor, S.E., 1994:
Pharmacologic considerations in the management of oral surgery patients in general dental practice

Wichtel, M.E.; Buys, E.; DeLuca, J.; Stringel, G., 1999 :
Pharmacologic considerations in the treatment of neonatal septicemia and its complications

Postelnick, M.; Halbur, S.R., 1998:
Pharmacologic considerations with antimicrobials used in oncology

Jolliet, P., 2000:
Pharmacologic constraints imposed by the blood-brain barrier: the example of multiple sclerosis

Magari, S.R.; Rivera, V.M.; Iuliucci, J.D.; Gilman, M.; Cerasoli, F., 1998:
Pharmacologic control of a humanized gene therapy system implanted into nude mice

Zoja, C.; Abbate, M.; Corna, D.; Capitanio, M.; Donadelli, R.; Bruzzi, I.; Oldroyd, S.; Benigni, A.; Remuzzi, G., 1998:
Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF-beta in experimental mesangioproliferative glomerulonephritis

Nedvídková, J.; Schreiber, V.; Stárka, L.; Pacák, K., 2001:
Pharmacologic control of hypophyseal tumors: interactions of estrogens, thyroid hormones, growth and anti-growth factors

Kovács, P.; Baricová, L.; Kovalová, M.; Dostál, J.; Stankovicová, T.; Svec, P., 1995:
Pharmacologic control of reperfusion dysrhythmias

Foegh, M.L.; Ramwell, P.W., 1998:
Pharmacologic control of smooth muscle cells in allografts

Krylov, I.N.; Iasnetsov, V.V.; Dukhanin, A.S.; Pal'tsev, I.P., 1993:
Pharmacologic correction of learning and memory disorders induced by exposure to high-frequency electromagnetic radiation

Stratienko, E.N., 2002:
Pharmacologic correction of physical ability to work under common and complicated conditions

Saniova, B., 1999:
Pharmacologic cytoprotection of the central nervous system

Wann, S-ren.; Weil, M.Harry.; Sun, S.; Tang, W.; Pellis, T., 2002:
Pharmacologic defibrillation

Spadari, M.; Tissot-Dupont, H.; Tichadou, L.; Arditti, J.; Jouglard, J.; David, J.M.; Gallais, H.; Valli, M., 2001:
Pharmacologic dependence on nefopam (Acupan): a case report

Liu, L.; Taverna, P.; Whitacre, C.M.; Chatterjee, S.; Gerson, S.L., 1999:
Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents

Ishida, Y.; Ishida, Y.; Heersche, J.N.M., 2002:
Pharmacologic doses of medroxyprogesterone may cause bone loss through glucocorticoid activity: an hypothesis

Bednarczuk, T.; Pietrzykowski, A.; Słoń, M.; Nauman, A., 1993:
Pharmacologic effect of excess iodine on type I thyroxine 5'-deiodinase activity in rat thyroid

Bertani, A.; Perna, G.; Arancio, C.; Caldirola, D.; Bellodi, L., 1997:
Pharmacologic effect of imipramine, paroxetine, and sertraline on 35% carbon dioxide hypersensitivity in panic patients: a double-blind, random, placebo-controlled study

Prado, M.E.; Streeter, R.N.; Mandsager, R.E.; Shawley, R.V.; Claypool, P.L., 2000:
Pharmacologic effects of epidural versus intramuscular administration of detomidine in cattle

Petócz, L., 1993:
Pharmacologic effects of tofizopam (Grandaxin)

Wu, C-Ying.; Yeh, H-Zen.; Chen, G-Hum., 2002:
Pharmacologic efficacy in gastric variceal rebleeding and survival: including multivariate analysis

Rummans, T.A.; Lauterbach, E.C.; Coffey, C.E.; Royall, D.R.; Cummings, J.L.; Salloway, S.; Duffy, J.; Kaufer, D., 1999:
Pharmacologic efficacy in neuropsychiatry: a review of placebo-controlled treatment trials. A report of the ANPA Committee on Research

Khoury, D.S.; Assar, M.D.; Sun, H., 1998:
Pharmacologic enhancement of atrial electrical defibrillation efficacy: role of ibutilide

Broderick, G.A.; Harkaway, R., 1994:
Pharmacologic erection: time-dependent changes in the corporal environment

Baudet, S.; Noireaud, J., 2000:
Pharmacologic evaluation of isometric contraction-relaxation coupling indexes in rabbit ventricular muscle

Racanská, E.; Kozlovský, J., 1994:
Pharmacologic evaluation of p-hydroxyacetophenone derivatives as potential beta-adrenolytics

Missale, C.; Spano, P., 1996:
Pharmacologic evidence for D2 dopamine receptor heterogeneity

Afanas'ev, S.A.; Lishmanov, I.B.; Kondrat'ev, B.Iu.; Cherniavskiĭ, A.M.; Karpov, R.S., 1997:
Pharmacologic evidence for disorders of myocardial adrenoreactivity in chronic coronary ischemia

Mackenzie, I.M.; Banning, A.; Dyar, O., 2001:
Pharmacologic exposure of an occult atrial septal defect

Kuster, G.G.; Fischer, B., 1993 :
Pharmacologic hemostasis in laparoscopy: topical epinephrine facilitates cholecystectomy

Lambrigts, D.; Van Calster, P.; Xu, Y.; Awwad, M.; Neethling, F.A.; Kozlowski, T.; Foley, A.; Watts, A.; Chae, S.J.; Fishman, J.; Thall, A.D.; White-Scharf, M.E.; Sachs, D.H.; Cooper, D.K., 1999:
Pharmacologic immunosuppressive therapy and extracorporeal immunoadsorption in the suppression of anti-alphaGal antibody in the baboon

Beránek, M.; Palicka, V., 1998:
Pharmacologic importance of glycation of plasma proteins

Carré, A., 1998:
Pharmacologic importance of the combination atenolol/nifedipine in hypertensive patients

Wieslander, E.; Delander, E.L.; Järkelid, L.; Hjertberg, E.; Tunek, A.; Brattsand, R., 1998:
Pharmacologic importance of the reversible fatty acid conjugation of budesonide studied in a rat cell line In vitro

Atweh, G.F.; Schechter, A.N., 2001:
Pharmacologic induction of fetal hemoglobin: raising the therapeutic bar in sickle cell disease

Lowrey, T.S.; Dunlap, A.W.; Brown, R.O.; Dickerson, R.N.; Kudsk, K.A., 1996:
Pharmacologic influence on nutrition support therapy: use of propofol in a patient receiving combined enteral and parenteral nutrition support

Boroojerdi, B., 2002:
Pharmacologic influences on TMS effects

Horowitz, S.M.; Algan, S.A.; Purdon, M.A., 1996:
Pharmacologic inhibition of particulate-induced bone resorption

Press, R.D., 2001:
Pharmacologic inhibition of the Bcr-Abl kinase with STI571: a novel, safe, and effective therapy for chronic myeloid leukemia

Ahn, N.G.; Nahreini, T.S.; Tolwinski, N.S.; Resing, K.A., 2001:
Pharmacologic inhibitors of MKK1 and MKK2

Leyland-Jones, B.; Arnold, A.; Gelmon, K.; Verma, S.; Ayoub, J.P.; Seidman, A.; Dias, R.; Howell, J.; Rakhit, A., 2001:
Pharmacologic insights into the future of trastuzumab

Forejt, J.; Horácková, M.; Hása, J.; Safárová, R.; Vanková, S.; Votocek, J., 2002:
Pharmacologic insult as a cause of acute kidney failure with a need for acute hemodialysis therapy

Calvet, A.; Díez de Ulzurrun, M.; Pérez, M.T.; Esteras, J., 2001:
Pharmacologic interactions in chronic treatments: corrective measures for its prevention in a basic area of rural health

Joos, A.A., 1998:
Pharmacologic interactions of antibiotics and psychotropic drugs

Davis, J.M.; Rosenfeld, W.N.; Koo, H.C.; Gonenne, A., 1994:
Pharmacologic interactions of exogenous lung surfactant and recombinant human Cu/Zn superoxide dismutase

Filardi, P.P.; Chiariello, M., 1996:
Pharmacologic interactions with nitrates in patients with, or at risk of, cardiac decompensation

Dent, P.; Grant, S., 2001:
Pharmacologic interruption of the mitogen-activated extracellular-regulated kinase/mitogen-activated protein kinase signal transduction pathway: potential role in promoting cytotoxic drug action

Nader, A.; Grace, N.D., 1999:
Pharmacologic intervention during the acute bleeding episode

Marchetti, A.; Wechsler, A.S., 1996:
Pharmacologic intervention for acute low cardiac output

Kim, C.K., 1997:
Pharmacologic intervention for the diagnosis of acute cholecystitis: cholecystokinin pretreatment or morphine, or both?

Viamontes, C.M., 1996:
Pharmacologic intervention in the management of preterm labor: an update

Pieper, J.A., 2001:
Pharmacologic interventions for coronary artery disease and risk factors. Introduction

Matte, G.G.; Barnes, D.C.; Abrams, D.N., 2001:
Pharmacologic interventions in nuclear medicine assessment of cardiac perfusion

Saremi, F.; Jadvar, H.; Siegel, M.E., 2002:
Pharmacologic interventions in nuclear radiology: indications, imaging protocols, and clinical results

Auer, J.; Berent, R.; Weber, T.; Porodko, M.; Mayr, H.; Maurer, E.; Eber, B., 2001:
Pharmacologic interventions in primary prevention: lipid lowering drugs, aspirin, antiobesity drugs, and antihypertensive agents

Tondo, L.; Ghiani, C.; Albert, M., 2002:
Pharmacologic interventions in suicide prevention

Gleason, M.S., 1996:
Pharmacologic issues in aging

Jindal, N.; Hollenberg, S.M.; Dellinger, R.P., 2000:
Pharmacologic issues in the management of septic shock

Keck, P.E.; McElroy, S.L.; Bennett, J.A., 2001:
Pharmacologic loading in the treatment of acute mania

López Gil, M.; Arribas, F.; Hernández Afonso, J.; Angel Santos, M.; García-Cosío, F., 1996:
Pharmacologic maintenance of sinusal rhythm and/or control of the ventricular response in patients with atrial fibrillation or flutter

Flynn, B.L.; Theesen, K.A., 1999:
Pharmacologic management of Alzheimer disease part III: nonsteroidal antiinflammatory drugs--emerging protective evidence?

Kumar, V.; Durai, N.B.; Jobe, T., 1998:
Pharmacologic management of Alzheimer's disease

Moran, G.J., 2000:
Pharmacologic management of HIV/STD exposure

Barkin, R.L.; Barkin, D., 2001:
Pharmacologic management of acute and chronic pain: focus on drug interactions and patient-specific pharmacotherapeutic selection

Gearhart, M., 2002:
Pharmacologic management of agitation in the older adult with dementia

Rutherford, J.D., 1993:
Pharmacologic management of angina and acute myocardial infarction

Calhoun, L.K., 1996:
Pharmacologic management of apnea of prematurity

Fagan, K.M., 1998:
Pharmacologic management of athletic amenorrhea

Lichtblau, L.; Belgrade, M.; Auld, R.; Elliott, T.E., 1996:
Pharmacologic management of cancer pain in rural Minnesota

Davis, L.; Stecy, P., 1997:
Pharmacologic management of cardiovascular problems in women

Sikes, P.J.; Nolan, S., 1993:
Pharmacologic management of cerebral vasospasm

Brucker, M.C.; Faucher, M.A., 1997:
Pharmacologic management of common gastrointestinal health problems in women

Llanes-Oberstein, A., 1997:
Pharmacologic management of common health problems in women. A professional evolution

Mays, M.; Leiner, S., 1997:
Pharmacologic management of common lower respiratory tract disorders in women

Kriebs, J.M.; Burgin, K.B., 1997:
Pharmacologic management of common musculoskeletal disorders in women

Bright, D.C., 1997:
Pharmacologic management of cytomegalovirus retinitis: review of current and future therapeutic modalities

Davis, K.M.; Mathew, E., 1998:
Pharmacologic management of depression in the elderly

Bourdet, S.V.; Gidal, B.E.; Alldredge, B.K., 2001:
Pharmacologic management of epilepsy in the elderly

Ozuna, J., 1997:
Pharmacologic management of epilepsy: an update

Ramakrishnan, A.; Katz, P.O., 2002:
Pharmacologic management of gastroesophageal reflux disease

Croft, J.B.; Giles, W.H.; Roegner, R.H.; Anda, R.F.; Casper, M.L.; Livengood, J.R., 1997:
Pharmacologic management of heart failure among older adults by office-based physicians in the United States

Moser, D.K., 1993:
Pharmacologic management of heart failure: neurohormonal agents

Cross, J.A., 1993:
Pharmacologic management of heart failure: positive inotropic agents

Mamdani, F.S., 1994:
Pharmacologic management of herpes zoster and postherpetic neuralgia

Ross, B.S.; Fischer, R.G., 1998:
Pharmacologic management of hypertension. Choosing an initial therapy

Pepper, G.A., 1999:
Pharmacologic management of intractable pain

Marin, P.A., 1999:
Pharmacologic management of migraine

D'Apolito, K.C.; McRorie, T.I., 1996:
Pharmacologic management of neonatal abstinence syndrome

Bruera, E.; Beattie-Palmer, L.N., 2001 :
Pharmacologic management of nonpain symptoms in surgical patients

Stanley, K.L.; Weaver, J.E., 1998:
Pharmacologic management of pain and inflammation in athletes

Ray, J.B., 2001:
Pharmacologic management of pain: the surgeon's responsibility

Goodwin, S.A., 2002:
Pharmacologic management of patients undergoing conscious sedation

Ostrowski, D.J.; DeNelsky, G.Y., 1996:
Pharmacologic management of patients using smoking cessation aids

Sherman, R.G.; Lasseter, D.H., 1996:
Pharmacologic management of patients with diseases of the endocrine system

Nygaard, I.E., 1999:
Pharmacologic management of pelvic floor dysfunction

Mariotti, A.; Monroe, P.J., 1998:
Pharmacologic management of periodontal diseases using systemically administered agents

McNamara, D.B.; Champion, H.C.; Kadowitz, P.J., 1998:
Pharmacologic management of peripheral vascular disease

Madrid, A.L.; State, M.W.; King, B.H., 2000:
Pharmacologic management of psychiatric and behavioral symptoms in mental retardation

Roe, V.A.; Gudi, A., 1997:
Pharmacologic management of sexually transmitted diseases

Malseed, R.T.; Wilson, B.A., 1993:
Pharmacologic management of systemic lupus erythematosus: nursing implications

DeJesus, J.M.; Tsuchiya, C., 1999:
Pharmacologic management of the arthritic foot and ankle

Cowper, T.R., 1996:
Pharmacologic management of the patient with disorders of the cardiovascular system. Infective endocarditis

Quinn, L., 2001:
Pharmacologic management of the patient with type 2 diabetes

Pearson, H.A., 1996:
Pharmacologic manipulation of fetal hemoglobin levels in sickle cell diseases and thalassemia: promise and reality

Hayden, R.E.; Snyder, B.J., 1993:
Pharmacologic manipulation of random skin flaps with pentoxifylline

Gory-Delabaere, G.; Cupissol, D.; Brès, J.; Gau, F.; Constans, B.; Nouguier-Soulé, J., 2000:
Pharmacologic markers predictive of neutropenia chemically induced by cisplatin (CDDP)

Sanchez-Ramos, L.; Hsieh, E., 2003:
Pharmacologic methods for cervical ripening and labor induction

Nordt, S.Patrick.; Williams, S.R.; Clark, R.F., 2002:
Pharmacologic misadventure resulting in hypercalcemia from vitamin D intoxication

Danion, J.M.; Vidailhet, P., 2000:
Pharmacologic models of memory disorders in pathology

Chollet, F.; Loubinoux, I.; Pariente, J.; Carel, C.; Albucher, J.F.; Rascol, O.; Guiraud-Chaumeil, B., 2001:
Pharmacologic modification of cerebral activity: value of functional neuroimaging

Lehmann, C.; Luther, B.; Kox, W.J., 1996:
Pharmacologic modification of intestinal reperfusion injury in the animal experiment

Moulder, J.E.; Robbins, M.E.; Cohen, E.P.; Hopewell, J.W.; Ward, W.F., 1998:
Pharmacologic modification of radiation-induced late normal tissue injury

Miura, M.; Kobayashi, M., 1994:
Pharmacologic modification of reperfusion injury

Aronson, D., 1997:
Pharmacologic modulation of autonomic tone: implications for the diabetic patient

Steinberg, M.H.; Rodgers, G.P., 2001:
Pharmacologic modulation of fetal hemoglobin

Chollet, F., 2001:
Pharmacologic modulation of human cerebral activity: contribution of functional neuroimaging

Hirko, M.K.; McShannic, J.R.; Schmidt, S.P.; Sharp, W.V.; Evancho, M.M.; Sims, R.L.; Siebert, J.D., 1993:
Pharmacologic modulation of intimal hyperplasia in canine vein interposition grafts

McCallum, R.W., 2000:
Pharmacologic modulation of motility

Miyachi, Y., 2000:
Pharmacologic modulation of neutrophil functions

Royer, R.J.; Pierfitte, C.; Hanesse, B., 1996:
Pharmacologic monitoring in elderly persons

Elliott, G.T., 1996:
Pharmacologic myocardial preconditioning with monophosphoryl lipid A (MLA) reduces infarct size and stunning in dogs and rabbits

Strauer, B.E.; Heidland, U.E.; Heintzen, M.P.; Schwartzkopff, B., 1995:
Pharmacologic myocardial protection during percutaneous transluminal coronary angioplasty (PTCA) by intracoronary dipyridamole: hemodynamic, contractile and dynamic ventricular consequences

de Haan, P.; Kalkman, C.J.; Jacobs, M.J., 2001:
Pharmacologic neuroprotection in experimental spinal cord ischemia: a systematic review

Conrad, M.H.; Adams, W.P., 2001:
Pharmacologic optimization of microsurgery in the new millennium

Perazella, M.A., 2001:
Pharmacologic options available to treat symptomatic intradialytic hypotension

Schapiro, R.T., 2002:
Pharmacologic options for the management of multiple sclerosis symptoms

Campbell, M.L.; Mathys, M.L., 2001:
Pharmacologic options for the treatment of obesity

Pimlott, N.J., 2000:
Pharmacologic or behavioural therapy for elderly people's insomnia. Which is better?

Breitbart, W.; McDonald, M.V., 1996:
Pharmacologic pain management in HIV/AIDS

Maikler, V.E., 1998:
Pharmacologic pain management in children: a review of intervention research

Felder, M., 1998:
Pharmacologic pain treatment

Curatolo, M.; Bogduk, N., 2001:
Pharmacologic pain treatment of musculoskeletal disorders: current perspectives and future prospects

Johnson, D.L., 1998:
Pharmacologic pain. Management for cancer patients at home

Truog, R.D.; Burns, J.P.; Mitchell, C.; Johnson, J.; Robinson, W., 2000:
Pharmacologic paralysis and withdrawal of mechanical ventilation at the end of life

Llop Rius, R.; Martí Jubilla, R.; Nualart Feliu, M.; Violan Fors, C., 2000:
Pharmacologic prescription in 3 geriatric homes in Barcelona

Levy, J.H., 2001:
Pharmacologic preservation of the hemostatic system during cardiac surgery

Capriotti, T., 2000:
Pharmacologic prevention and treatment of osteoporosis in women

Wheeldon, N.; Cumberland, D., 1997:
Pharmacologic prevention of acute ischemic complications of coronary angioplasty

Milani, R.V.; Lavie, C.J., 1996:
Pharmacologic prevention of coronary artery disease. What do clinical trials show?

Zikmund, J., 1993:
Pharmacologic prevention of postoperative cystitis

Himmelfarb, J., 1999:
Pharmacologic prevention of vascular access stenosis

Estler, C.J., 1995:
Pharmacologic principles of drug prescribing in pregnancy

Porciani, P.F., 1998:
Pharmacologic problems in xerostomia in the elderly

Idee, J.M.; Bault, C.; Beaufils, H.; Berthommier, C.; Cambar, J.; Corot, C.; Doucet, D.; Hartl, C.; Jaudon, M.C.; Jacquiaud, C.; Lakhdar, B.; Potier, M.; santus, R.; Torcherie, S.; Vaudon, E.; Bonnemain, B., 1996:
Pharmacologic profile of iobitridol, a nonionic iodinated contrast medium

Okubo, M.; Yamane, K.; Kohno, N., 2002:
Pharmacologic profile of oral antidiabetic agents

Duvic, M., 1998:
Pharmacologic profile of tazarotene

Jeske, A.H.; Redden, R.E., 1993:
Pharmacologic profiles of primary emergency drugs

Inada, Y.; Ojima, M.; Kanagawa, R.; Misumi, Y.; Nishikawa, K.; Naka, T., 1999:
Pharmacologic properties of candesartan cilexetil--possible mechanisms of long-acting antihypertensive action

Kotake, Y., 2001:
Pharmacologic properties of phenyl N-tert-butylnitrone

Smith, M.N., 1997:
Pharmacologic properties of venlafaxine

Flannery, J.; Tucker, D.A., 2002:
Pharmacologic prophylaxis and treatment of stress ulcers in critically ill patients

Klimenko, V.N.; Belenichev, I.F.; Bashkin, I.N.; Shavrin, V.A.; Vizir, V.A.; Guĭtur, M.M., 1993:
Pharmacologic protection of brain in surgery of the brachiocephalic arteries

Leonard, M., 2000:
Pharmacologic protocol varies for LASIK

Navare, S.M.; Kapetanopoulos, A.; Heller, G.V., 2002:
Pharmacologic radionuclide myocardial perfusion imaging

Nagelhout, J.J.; Boytim, M.J., 2001:
Pharmacologic rationale for anesthetic agents in ambulatory practice

Möbius, H.J., 1999:
Pharmacologic rationale for memantine in chronic cerebral hypoperfusion, especially vascular dementia

Leeper-Woodford, S.K.; Fisher, B.J.; Sugerman, H.J.; Fowler, A.A., 1993:
Pharmacologic reduction in tumor necrosis factor activity of pulmonary alveolar macrophages

Qureshi, A.I.; Wilson, D.A.; Hanley, D.F.; Traystman, R.J., 1999:
Pharmacologic reduction of mean arterial pressure does not adversely affect regional cerebral blood flow and intracranial pressure in experimental intracerebral hemorrhage

Antonio Francischetti, E.; Genelhu Fagundes, V.; Francischetti, A., 1995:
Pharmacologic regression of cardiac and vascular structural changes in the hypertensive patient. A question that goes beyond the exclusive medical bias

Rayan, G.M.; Parizi, M.; Tomasek, J.J., 1996:
Pharmacologic regulation of Dupuytren's fibroblast contraction in vitro

Vinogradova, L.F.; Illarionova, T.S.; Kharlitskaia, E.V.; Burobina, S.S.; Berezov, T.T., 1998:
Pharmacologic regulation of hepatocyte cytolysis by antioxidants during acute D-galactosamine hydrochloride intoxication

Van Wagoner, D.R., 2000:
Pharmacologic relevance of K(+)Channel remodeling in atrial fibrillation

Ceccarelli, G., 1994:
Pharmacologic remedies, cosmetics, and clinical pharmacology in the Bible

Martínez Sánchez, C., 2001:
Pharmacologic reperfusion in acute myocardial infarction

Zeitlin, P.L., 2000:
Pharmacologic restoration of delta F508 CFTR-mediated chloride current

Staerman, F.; Bryckaert, P.E.; Youinou, Y.; Colin, J.; Brandt, B.; Lardennois, B., 2002:
Pharmacologic stimulation of ejaculation with midodrine hydrochloride (Gutron) for medically assisted reproduction in spinal injury

Abreu, A., 1994:
Pharmacologic stimulation with adenosine and dipyridamole

Rifkin, A., 1993:
Pharmacologic strategies in the treatment of schizophrenia

Varga, A., 2000 :
Pharmacologic stress echocardiography: can we forget "state-of-the-art" protocols?

Verani, M.S., 1993:
Pharmacologic stress myocardial perfusion imaging

Samady, H.; Wackers, F.J.Th.; Joska, T.M.; Zaret, B.L.; Jain, D., 2002:
Pharmacologic stress perfusion imaging with adenosine: role of simultaneous low-level treadmill exercise

McGuinness, M.E.; Talbert, R.L., 1994:
Pharmacologic stress testing: experience with dipyridamole, adenosine, and dobutamine

Iskandrian, A.S.; Verani, M.S.; Heo, J., 1994:
Pharmacologic stress testing: mechanism of action, hemodynamic responses, and results in detection of coronary artery disease

White, M.P., 1999:
Pharmacologic stress testing: understanding the options

Cerqueira, M.D., 1996:
Pharmacologic stress versus maximal-exercise stress for perfusion imaging: which, when, and why?

Huang, J.; Qiu, J.; Huang, J., 2003:
Pharmacologic studies on processed snakegall

Fushida, S.; Nao, F.; Kinami, S.; Ninomiya, I.; Fujimura, T.; Nishimura, G.; Ohta, T.; Yokogawa, K.; Miyamoto, K.; Miwa, K., 2002:
Pharmacologic study of intraperitoneal docetaxel in gastric cancer patients with peritoneal dissemination

Fushida, S.; Furui, N.; Kinami, S.; Ninomiya, I.; Fujimura, T.; Nishimura, G.; Ohta, T.; Yokogawa, K.; Miyamoto, K.; Miwa, K., 2002:
Pharmacologic study of intraperitoneal paclitaxel in gastric cancer patients with peritoneal dissemination

Zuskin, E.; Mustajbegović, J.; Sitar-Srebocan, V., 1997:
Pharmacologic study of the effects of the components of beer in vitro

Philibert, D.; Bouchoux, F.; Cerede, E.; Corallo, F.; Allaire, J.M., 1993:
Pharmacologic study of the glucocorticoid activity of flunisolide compared with other steroids in the rat

Ferlinz, R., 1997:
Pharmacologic substances for bronchial provocation testing

Tempe, D.K.; Virmani, S., 2000:
Pharmacologic support of circulation in patients undergoing cardiac surgery

Kershenovich Sefchovich, R.; Kably Ambe, A.; García Morales, M.A.; Peryra Quiñones, R.; Barrón Vallejo, J., 1997:
Pharmacologic suppression of the ovarian function and its clinical usefulness

Alvarez Requejo, A.; Martín Arias, L.H.; Carvajal García-Pando, A., 1996:
Pharmacologic surveillance and public health surveillance

Levy, G., 1994:
Pharmacologic target-mediated drug disposition

Mathis, J.M.; Barr, J.D., 1999:
Pharmacologic testing as an adjunct to neuroendovascular procedures

Perini, G.; Pozzoli, M., 1995:
Pharmacologic tests in cardiac decompensation

Von Feldt, J.M.; Ehrlich, G.E., 1999:
Pharmacologic therapies

Fonarow, G.C., 2002:
Pharmacologic therapies for acutely decompensated heart failure

Laird, J.R., 2000:
Pharmacologic therapies in the treatment of peripheral vascular disease: clinical experience with reteplase, a third-generation thrombolytic

Karlowicz, K.A., 1997:
Pharmacologic therapy for acute cystitis in adults: a review of treatment options

Rapaport, E., 1997:
Pharmacologic therapy for acute myocardial infarction. Which agent, how much, how soon, how long?

Madoff, R.D., 1998:
Pharmacologic therapy for anal fissure

Stoloff, S.W., 2000:
Pharmacologic therapy for asthma

Tariot, P.N.; Ryan, J.M.; Porsteinsson, A.P.; Loy, R.; Schneider, L.S., 2001:
Pharmacologic therapy for behavioral symptoms of Alzheimer's disease

Hansen, W.F.; Yankowitz, J., 2002:
Pharmacologic therapy for medical disorders during pregnancy

Goldberg, S.H.; Von Feldt, J.M.; Lonner, J.H., 2002:
Pharmacologic therapy for osteoarthritis

Nishimura, K.; Ikeda, A.; Koyama, H.; Tsukino, M.; Hajiro, T.; Izumi, T., 1996:
Pharmacologic therapy for patients with stable chronic obstructive pulmonary disease--emphasis on inhaled agents

Berg, T.G.; Smith, C.V., 2002:
Pharmacologic therapy for peripartum emergencies

Lowe, R.C.; Grace, N.D., 2001:
Pharmacologic therapy for portal hypertension

Sisson, M.C.; Sauer, P.M., 1996:
Pharmacologic therapy for pregnancy-induced hypertension

Gattone, M., 2001:
Pharmacologic therapy for smoking cessation

Schwartz, J.B., 2002:
Pharmacologic therapy for the older patient with cardiovascular disease: new information and continued challenges

McClung, B.; McClung, M., 2001:
Pharmacologic therapy for the treatment and prevention of osteoporosis

Ghoniem, G.M., 1996:
Pharmacologic therapy for urinary incontinence

Portera, S.G.; Lipscomb, G.H., 1998:
Pharmacologic therapy for urinary incontinence and voiding dysfunctions

Pettenati, C., 2001:
Pharmacologic therapy in the elderly

Hoogerwerf, W.A.; Pasricha, P.J., 2001:
Pharmacologic therapy in treating achalasia

Banai, J., 2000:
Pharmacologic therapy of Crohn's disease and ulcerative colitis

Van Cutsem, E.; Piessevaux, H., 1996:
Pharmacologic therapy of arteriovenous malformations

Kiełbiński, M., 1994:
Pharmacologic therapy of bone tissue changes due to hematologic malignancies and bone metastasis

Catapano, S.; Gavagna, M.; Baldissara, S.; Baldissara, P., 1998:
Pharmacologic therapy of cranio-cervico-mandibular disorders. Review of the literature

Kaufer, D.I., 2002:
Pharmacologic therapy of dementia with Lewy bodies

Goncalvesova, E.; Fabian, J., 2001:
Pharmacologic therapy of heart failure

Ceska, R., 1993:
Pharmacologic therapy of hyperlipoproteinemia and its pitfalls

Aronow, W.S., 2002:
Pharmacologic therapy of lipid disorders in the elderly

Pelletier, J.P.; Choquette, D.; Haraoui, B.; Raynauld, J.P.; Rich, E.; Fernandes, J.C.; Martel-Pelletier, J., 2000:
Pharmacologic therapy of osteoarthritis

Kushida, K., 1994:
Pharmacologic therapy of osteoporosis

Saal, J.G., 1993:
Pharmacologic therapy of rheumatoid arthritis with delayed-action anti-rheumatic drugs

Kiowski, W.; Sütsch, G.; Fatio, R.; Schalcher, C.; Brunner-LaRocca, H.P., 1998:
Pharmacologic therapy of severe heart failure

Pagni, C.A.; Cossandi, C.; Fontanella, M.; Griva, F.; Zullo, N., 1998:
Pharmacologic therapy of subarachnoid hemorrhage

Mushkat, Y.; Gordon, D.; David, M.P., 1994:
Pharmacologic therapy of urinary retention after vaginal operations

Haverkamp, W.; Borggrefe, M.; Block, M.; Böcker, D.; Breithardt, G., 1996:
Pharmacologic therapy of ventricular tachyarrhythmias: value of class III anti-arrhythmia drugs

Sheftell, F.D., 1993:
Pharmacologic therapy, nondrug therapy, and counseling are keys to effective migraine management

Jerjes-Sánchez, C.; Garza-Ruíz, A.; Gutiérrez-Fajardo, P., 2000:
Pharmacologic thrombolysis in acute myocardial infarction: lessons learned after ISIS-2 and GUSTO-I. Part II

Andriulli, A.; Leandro, G.; Niro, G.; Mangia, A.; Festa, V.; Gambassi, G.; Villani, M.R.; Facciorusso, D.; Conoscitore, P.; Spirito, F.; D.M.io, G., 2000:
Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis

Birmaher, B.; Yelovich, A.K.; Renaud, J., 1999:
Pharmacologic treatment for children and adolescents with anxiety disorders

Lestage, P., 2000:
Pharmacologic treatment for cognitive disorders: an update

Lai, H.Henry.; Boone, T.B.; Appell, R.A., 2002:
Pharmacologic treatment for detrusor overactivity

Maciejewska, M., 1995:
Pharmacologic treatment for polycystic ovary syndrome

Halawa, B., 1997:
Pharmacologic treatment for ventricular arrhythmias

García de Yébenes, J.; Fontán, A.; Rojo, A., 1999:
Pharmacologic treatment in Parkinson disease

Borghi, C.; Bacchelli, S., 2002:
Pharmacologic treatment in elderly patients with heart failure. Which precautions?

Atik, E., 2003:
Pharmacologic treatment in pediatric cardiology. Advances and specific management of each syndrome

Díez, J.J., 1998:
Pharmacologic treatment of Cushing's syndrome

Whalen, D.A.; Izzi, G., 1993:
Pharmacologic treatment of acute congestive heart failure resulting from left ventricular systolic or diastolic dysfunction

Schieweck, A.; Gunschera, J.; Varol, D.; Salthammer, T., 2018:
Analytical procedure for the determination of very volatile organic compounds (C3-C6) in indoor air

Foley, J.J., 1993:
Pharmacologic treatment of acute migraine and related headaches in the emergency department

Fernando, P.B.; Ferreira, A.; Dias, P.; Moura, L.; Cortez, M.; Capucho, R.; Maciel, M.J.; Brandão, F.; Gomes, M.C., 1996:
Pharmacologic treatment of acute myocardial infarction: 2 large clinical trials at a central hospital

Faden, A.I., 1996:
Pharmacologic treatment of acute traumatic brain injury

Lantz, M.S.; Marin, D., 1996:
Pharmacologic treatment of agitation in dementia: a comprehensive review

Johnson, J.R., 1997:
Pharmacologic treatment of alcohol withdrawal

Phillips, R., 2002:
Pharmacologic treatment of anal fissure with botoxin, diltiazem, or bethanechol

Velosa, J.F.; Riddle, M.A., 2000:
Pharmacologic treatment of anxiety disorders in children and adolescents

Marche, P.; Hérembert, T.; Zhu, D.L., 1998:
Pharmacologic treatment of atherosclerosis: beyond lipid-lowering therapy

Chiou-Tan, F.Y.; Lenz, M.L.; Robertson, C.S.; Grabois, M., 1994:
Pharmacologic treatment of autonomic dysreflexia in the rat

Castro Díaz, D., 1997:
Pharmacologic treatment of benign prostatic hyperplasia

Crippen, D.W., 1994:
Pharmacologic treatment of brain failure and delirium

Corcos, M.; Flament, M.; Atger, F.; Jeammet, P., 1996:
Pharmacologic treatment of bulimia

Bruera, E.; Fainsinger, R.L., 1997:
Pharmacologic treatment of cancer pain

Kudenchuk, P.J.; Racht, E.M., 1999:
Pharmacologic treatment of cardiac arrest

Scahill, L.; Lynch, K.A., 1995:
Pharmacologic treatment of children and adolescents with obsessive-compulsive disorder

Halawa, B., 1996:
Pharmacologic treatment of chronic congestive heart failure

Hutchinson, R., 1993:
Pharmacologic treatment of colonic pseudo-obstruction

Flint, A.J., 1997:
Pharmacologic treatment of depression in late life

Datto, C.J.; Oslin, D.W.; Streim, J.E.; Scheinthal, S.M.; DiFilippo, S.; Katz, I.R., 2002:
Pharmacologic treatment of depression in nursing home residents: a mental health services perspective

Cohen, L.S., 1998:
Pharmacologic treatment of depression in women: PMS, pregnancy, and the postpartum period

Santos Vicente, F.J.; Mearin Manrique, F., 1994:
Pharmacologic treatment of digestive hemorrhage caused by gastroduodenal mucosal lesions

McCormick, J.J.; Deeg, M.A., 2000:
Pharmacologic treatment of dyslipidemia

Davidoff, P., 1991:
Pharmacologic treatment of dyslipidemias: Analysis of initiation recommendations and drug selection

Smith, B.W.; LaBotz, M., 1998:
Pharmacologic treatment of exercise-induced asthma

Barkhuizen, A., 2001:
Pharmacologic treatment of fibromyalgia

Brawman-Mintzer, O., 2001:
Pharmacologic treatment of generalized anxiety disorder

McDonald, W.M.; Wermager, J., 2002:
Pharmacologic treatment of geriatric mania

Flynn, J.; Grieger, T.A.; Benedek, D.M., 2002:
Pharmacologic treatment of hospitalized patients with schizoaffective disorder

Gallart, L.; Rouby, J.J.; Puig, M.M., 1997:
Pharmacologic treatment of hypoxemia in adult respiratory distress syndrome

Francavilla, S.; Gabriele, A.; Oliveri, M.; Cordeschi, G.; Properzi, G., 1993:
Pharmacologic treatment of idiopathic oligoasthenoteratozoospermia

Lefebvre, P.P.; Staecker, H.; Van de Water, T.; Moonen, G.; Malgrange, B., 2002:
Pharmacologic treatment of inner ear: from basic science to the patient

Gmiński, J., 1996:
Pharmacologic treatment of lipid metabolism disorders

Dutkiewicz, S., 1996:
Pharmacologic treatment of mild proliferation of prostatic cancer

Klesmer, J.; Badescu, R., 2002:
Pharmacologic treatment of mood disorders in acquired immune deficiency syndrome (AIDS)

Rivera, V.M., 2001:
Pharmacologic treatment of multiple sclerosis

Mazzotta, P.; Gupta, A.; Maltepe, C.; Koren, G.; Magee, L., 1998:
Pharmacologic treatment of nausea and vomiting during pregnancy

Gabilan, J.C., 1998:
Pharmacologic treatment of neonatal jaundice. A new approach

Wallace, M.S., 2001:
Pharmacologic treatment of neuropathic pain

Flament, M.F., 1993:
Pharmacologic treatment of obsessive compulsive disorder in the child and adolescent

Flament, M.F.; Bisserbe, J.C., 1997:
Pharmacologic treatment of obsessive-compulsive disorder: comparative studies

Rodríguez Castellanos, F.Eugenio., 2002:
Pharmacologic treatment of patients with arterial hypertension. Parameters to be considered when choosing a therapeutic approach

Bracchetti, D.; Palmieri, M.; Guaragna, R., 2002:
Pharmacologic treatment of persistent atrial fibrillation

Graf, W.D.; Riback, P.S., 1995:
Pharmacologic treatment of recurrent pediatric headache

Quinn, L., 2002:
Pharmacologic treatment of the critically ill patient with diabetes

Goldchluk, Aíbal., 2002:
Pharmacologic treatment of the psychotic symptoms in schizophrenia

Scahill, L.; Chappell, P.B.; King, R.A.; Leckman, J.F., 2000:
Pharmacologic treatment of tic disorders

Wasielewski, P.G.; Burns, J.M.; Koller, W.C., 1998:
Pharmacologic treatment of tremor

Bloomgarden, Z.T., 2003:
Pharmacologic treatment of type 2 diabetes

Abdallah, M.P.; Hirbli, K., 2000:
Pharmacologic treatment of type 2 diabetes mellitus: realities and perspectives

Jurascheck, F., 1993:
Pharmacologic treatment of urinary dysfunctions

Moll, F., 1994:
Pharmacologic treatment of urinary incontinence in the elderly

Pons Rocher, F.; Mompó Romero, L.; Brotons Durban, S.; López Martínez, R., 2001:
Pharmacologic treatment of vertigo

Sirtori, C.R., 2002:
Pharmacologic treatment with statins

Pala, C.; Spano, G.; Bercovich, E., 1997:
Pharmacologic treatment, tolerance and quality of life. Data of the observational UroLink study

Bercovich, E., 1997:
Pharmacologic treatment, tolerance and quality of life. Update

Casacalenda, N.; Boulenger, J.P., 1998:
Pharmacologic treatments effective in both generalized anxiety disorder and major depressive disorder: clinical and theoretical implications

Kranzler, H.R.; Amin, H.; Modesto-Lowe, V.; Oncken, C., 1999:
Pharmacologic treatments for drug and alcohol dependence

Novack, G.D., 2002:
Pharmacologic treatments for dry eye: a worthwhile investment?

Glover, E.D.; Glover, P.N., 2001:
Pharmacologic treatments for the nicotine dependent smoker

Yue, H.W.; Hu, X.Q., 1996:
Pharmacologic value of radix Puerariae and puerarine on cardiovascular system

White, C.M., 1998:
Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors

Hande, K.R., 1993:
Pharmacologic-based dosing of carboplatin: a better method

Varughese, L.R.; Rajpoot, M.; Goyal, S.; Mehra, R.; Chhokar, V.; Beniwal, V., 2018:
Analytical profiling of mutations in quinolone resistance determining region of gyrA gene among UPEC

Buss, V.H.; Deeks, L.S.; Shield, A.; Kosari, S.; Naunton, M., 2018:
Analytical quality and effectiveness of point-of-care testing in community pharmacies: A systematic literature review

Taevernier, L.; Wynendaele, E.; D Hondt, M.; De Spiegeleer, B., 2015:
Analytical quality-by-design approach for sample treatment of BSA-containing solutions

Kelly; Antman, 2001:
Pharmacological Therapy of Cardiac Arrhythmias

Ohtsuka, N.; Urayama, K., 2003:
Pharmacological action and clinical effects of falecalcitriol, a highly potent derivative of active vitamin D3

Sekiguchi, N.; Ishii, Y.; Fujikura, H.; Hasegawa, Y.; Takayanagi, I., 1993:
Pharmacological action of (-)-(2S,3aR,7aS)-1-[(S)-N-[(S)-1-carbonyl-3- phenylpropyl]alanyl]hexahydro-2-indolinecarboxylic acid (trandolaprilat) in isolated smooth muscle preparations

Qian, B.C.; Chen, J.; Xu, H.J., 1994:
Pharmacological action of 101-B hair regeneration extract on skin and hair in experimental animals

Sekihara, H., 1994:
Pharmacological action of 9alpha-fluorohydrocortisone as a mineralocorticoid

Takada, M., 1994:
Pharmacological action of anabolic steroids

Potemski, P.; Płuzańska, A., 1999:
Pharmacological action of paclitaxel

Fang, Y.; Qu, L.; Zeng, W.; Song, J.; Xie, D.; Zhang, L., 1996:
Pharmacological action of siwei shaoyao decoction

Kumar, R.N.; Chambers, W.A.; Pertwee, R.G., 2001 :
Pharmacological actions and therapeutic uses of cannabis and cannabinoids

Singh, R.K.; Joshi, V.K.; Goel, R.K.; Gambhir, S.S.; Acharya, S.B., 1996:
Pharmacological actions of Pongamia pinnata seeds--a preliminary study

Li, X.; Zhou, Y.; Huang, X.; He, G.; Zhou, S.; Huang, H., 1997:
Pharmacological actions of different species form genus Pyrola

Youdim, M.B.; Finberg, J.P., 1994:
Pharmacological actions of l-deprenyl (selegiline) and other selective monoamine oxidase B inhibitors

Rossby, S.Paul.; Manier, D.Hal.; Liang, S.; Nalepa, I.; Sulser, F., 2001:
Pharmacological actions of the antidepressant venlafaxine beyond aminergic receptors

Auddy, B.; Alam, M.I.; Gomes, A., 1994:
Pharmacological actions of the venom of the Indian catfish (Plotosus canius Hamilton)

Shoji, M.; Oguni, Y.; Sato, H.; Morishita, S.; Ito, C.; Higuchi, M.; Sakanashi, M., 1993:
Pharmacological actions of "kyushin," a drug containing toad venom(2): effects on urinary volume and electrolyte excretion

Cascino, G.D., 1999:
Pharmacological activation

Rossignol, S.; Chau, C.; Brustein, E.; Giroux, N.; Bouyer, L.; Barbeau, H.; Reader, T.A., 1999:
Pharmacological activation and modulation of the central pattern generator for locomotion in the cat

Vedenina, V.Iu.; Heinrich, R.; Elsner, N., 2001:
Pharmacological activation of stridulation in Chorthippus albomarginatus (Orthoptera, Gomphocerinae)

Fox, S.W.; Hefti, F.; Hartikka, J.; Junard, E.; Przybylski, A.T.; Vaughan, G.; Fox, S.W., 1987:
Pharmacological activities in thermal proteins: relationships in molecular evolution

Colombo, M.L.; Bosisio, E., 1996:
Pharmacological activities of Chelidonium majus L. (Papaveraceae)

Suthar, A.C.; Banavalikar, M.M.; Biyani, M.K., 2003:
Pharmacological activities of Genistein, an isoflavone from soy (Glycine max): part I--anti-cancer activity

Suthar, A.C.; Banavalikar, M.M.; Biyani, M.K., 2003:
Pharmacological activities of Genistein, an isoflavone from soy (Glycine max): part II--anti-cholesterol activity, effects on osteoporosis & menopausal symptoms

Shim, J.Young.; Lee, Y.Sil.; Jung, S.Hoon.; Choi, H.Seok.; Shin, K.Hyun.; Kim, Y.Shik., 2003:
Pharmacological activities of a new glycosaminoglycan, acharan sulfate isolated from the giant African snail Achatina fulica

Lapchak, P.A.; Gash, D.M.; Collins, F.; Hilt, D.; Miller, P.J.; Araujo, D.M., 1997:
Pharmacological activities of glial cell line-derived neurotrophic factor (GDNF): preclinical development and application to the treatment of Parkinson's disease

Michel, A.; Laurent, F.; Chapat, J.P.; Boucard, M.; Bonnet, P.A., 1995:
Pharmacological activities of imidazo[1,2-alpha]pyrazine derivatives

Catapan, E.; Otuki, M.F.; Viana, A.M.; Yunes, R.A.; Bresciani, L.F.; Ferreira, J.; Santos, A.R.; Calixto, J.B.; Cechinel-Filho, V., 2001:
Pharmacological activity and chemical composition of callus culture extracts from selected species of Phyllanthus

Gao, Z.G.; Cui, W.Y.; Wang, L.; Liu, C.G., 1996:
Pharmacological activity and receptor-binding characteristics of 2 beta-(2'-phenyl-2'-cyclopentyl-2'-hydroxy-ethoxy)tropane and its optical isomers

Ko, F.N.; Yu, S.M.; Su, M.J.; Wu, Y.C.; Teng, C.M., 1993:
Pharmacological activity of (-)-discretamine, a novel vascular alpha-adrenoceptor and 5-hydroxytryptamine receptor antagonist, isolated from Fissistigma glaucescens

Yen, M.H.; Sheu, J.R.; Peng, I.H.; Lee, Y.M.; Chern, J.W., 1996:
Pharmacological activity of DC-015, a novel potent and selective alpha 1-adrenoceptor antagonist

Nowakowska, E.; Kus, K.; Chodera, A., 1996:
Pharmacological activity of fluoxetine

Nezhinskaia, G.I.; Sapronov, N.S., 2001:
Pharmacological activity of immunomodulators in adjuvant arthritis

Val'dman, E.A., 2000:
Pharmacological activity of the new adamantane derivative--potential antiparkinson preparation during subchronic administration

Watson, A.; Vandekerckhove, P.; Lilford, R., 2002:
Pharmacological adjuvants during infertility surgery: a systematic review of evidence derived from randomized controlled trials

Noda, J.; Otagiri, M.; Akaike, T.; Maeda, H., 1996:
Pharmacological advantages of conjugation of Cu, Zn-superoxide dismutase with succinylated keratin fragment: improvement of biological properties and resistance to oxidative damage

Higashino, K.; Moriwaki, Y., 1996:
Pharmacological agents affecting uric acid metabolism

Spence, R.K.; Cernaianu, A.C., 1994:
Pharmacological agents as adjuncts to bloodless vascular surgery

Dewhurst, A.T.; Moore, S.J.; Liban, J.B., 2002:
Pharmacological agents as cerebral protectants during deep hypothermic circulatory arrest in adult thoracic aortic surgery. A survey of current practice

Vasil'ev, P.V.; Glod, G.D.; Sytnik, S.I., 1993:
Pharmacological agents for maintaining the work capacity of flight personnel under extreme emotional stress

Vasil'ev, P.V.; Glod, G.D.; Sytnik, S.I., 1993:
Pharmacological agents for the correction of the processes of work capacity rehabilitation in flight personnel

Wein, A.J., 2000:
Pharmacological agents for the treatment of urinary incontinence due to overactive bladder

Ho, K.; Abourjaily, H.M., 2001:
Pharmacological aids for smoking cessation

Anonymous, 2000:
Pharmacological aids to smoking cessation

Keogh, J.P.; Zirvi, K.A.; Vossough, S.; Slomiany, A.; Slomiany, B.L., 1993:
Pharmacological alterations of cellular transglutaminase activity and invasiveness in human colorectal carcinoma cells

Waikar, M.V.; Hegde, S.S.; Ford, A.P.; Clarke, D.E., 1993:
Pharmacological analyses of endo-6-methoxy-8-methyl-8-azabicyclo[3.2.1]oct-3-yl-2,3-dihydro-2-oxo-1 H- benzimidazole-1-carboxylate hydrochloride (DAU 6285) at the 5-hydroxytryptamine4 receptor in the tunica muscularis mucosae of rat esophagus and ileum of guinea pig: role of endogenous 5-hydroxytryptamine

Kingston, A.E.; Burnett, J.P.; Mayne, N.G.; Lodge, D., 1995:
Pharmacological analysis of 4-carboxyphenylglycine derivatives: comparison of effects on mGluR1 alpha and mGluR5a subtypes

Nilsson, I.; Monstein, H.Jürg.; Lindström, E.; Håkanson, R.; Svensson, S., 2001:
Pharmacological analysis of CCK(2) receptor ligands using COS-7 and SK-N-MC cells, expressing the human CCK(2) receptor

Pérez-Saad, H.; Urba-Holmgren, R.; Holmgren, B., 1996:
Pharmacological analysis of acute morphine dependence in infant rats: close molecular relationship of head-shaking precipitated by opiate antagonists and cholinergic neurotransmission

Horinouchi, T.; Tsujitani, M.; Koike, K., 2000:
Pharmacological analysis of atypical beta-adrenoceptors in the guinea pig gastrointestinal tissue systems

Gardner, B.; Hall, D.A.; Strange, P.G., 1996:
Pharmacological analysis of dopamine stimulation of [35S]-GTP gamma S binding via human D2short and D2long dopamine receptors expressed in recombinant cells

Ando, M.; Minami, H.; Ando, Y.; Sakai, S.; Shimono, Y.; Sugiura, S.; Saka, H.; Shimokata, K.; Hasegawa, Y., 1999:
Pharmacological analysis of etoposide in elderly patients with lung cancer

Halmai, V.; Tabrizi, A.L.; Horváth, O.P.; Barthó, L., 1996:
Pharmacological analysis of nerves supplying the oesophagus

Julien, J.Y.; Barbeau, G., 1981:
Pharmacological analysis of patient's charts in a long-term care hospital

Moebius, F.F.; Reiter, R.J.; Bermoser, K.; Glossmann, H.; Cho, S.Y.; Paik, Y.K., 1998:
Pharmacological analysis of sterol delta8-delta7 isomerase proteins with [3H]ifenprodil

Khrapak, V.V.; Oliĭnyk, S.A.; Shevchenko, V.Ie.; Shtemenko, N.I.; Shtemenko, O.V., 2002:
Pharmacological analysis of the antihypoxic action of aminobutyric acid derivatives

Yang, X.P.; Chiba, S., 1999:
Pharmacological analysis of the double peaked vasoconstrictor responses to periarterial electric stimulation

Bowen, C.A.; Grant, K.A., 1998:
Pharmacological analysis of the heterogeneous discriminative stimulus effects of ethanol in rats using a three-choice ethanol-dizocilpine-water discrimination

Wesołowska, A.; Borycz, J.; Paluchowska, M.H.; Chojnacka-Wójcik, E., 2003:
Pharmacological analysis of the hypothermic effects of NAN-190 and its analogs, postsynaptic 5-HT1A receptor antagonists, in mice

Christopoulos, A.; Mitchelson, F., 1998:
Pharmacological analysis of the mode of interaction of McN-A-343 at atrial muscarinic M2 receptors

Kuz'min, A.I.; Lodygin, D.N.; Kalenikova, E.I.; Bychkova, E.Iu.; Khokhlova, O.N.; Murashev, A.N.; Medvedev, O.S., 2000:
Pharmacological analysis of the role of central alpha-2 adrenergic and imidazoline receptors in mechanism of the hypotensive effect of clonidine in rats

Bolshakov, K.V.; Buldakova, S.L., 2001:
Pharmacological analysis of the subunit composition of the AMPA receptor in hippocampal neurons

Yang, X.P.; Chiba, S., 2000:
Pharmacological analysis of vasoconstrictor responses to periarterial purinergic nerve stimulation

Nakane, T.; Chiba, S., 1993:
Pharmacological analysis of vasodilation induced by extracellular adenosine 3',5'-cyclic monophosphate in the isolated and perfused canine coronary artery

Loring, R.H.; Zigmond, R.E., 1990:
Pharmacological and Biochemical Properties of Nicotinic Receptors from Chick Retina

Knoflach, F.; Backus, K.H.; Giller, T.; Malherbe, P.; Pflimlin, P.; Möhler, H.; Trube, G., 1992:
Pharmacological and Electrophysiological Properties of Recombinant GABAA Receptors Comprising the alpha3, beta1 and gamma2 Subunits

Brudzynski, S.M., 2002:
Pharmacological and behavioral characteristics of 22 kHz alarm calls in rats

Carroll, M.E., 1994:
Pharmacological and behavioral treatment of cocaine addiction: animal models

Grazzi, L.; D'Amico, D.; Leone, M.; Moschiano, F.; Bussone, G., 2000:
Pharmacological and behavioral treatment of pediatric migraine and tension-type headache

Corrigan, P.W.; Yudofsky, S.C.; Silver, J.M., 1993:
Pharmacological and behavioral treatments for aggressive psychiatric inpatients

Varani, K.; Gessi, S.; Dalpiaz, A.; Borea, P.A., 1996:
Pharmacological and biochemical characterization of purified A2a adenosine receptors in human platelet membranes by [3H]-CGS 21680 binding

Bach, M.; Sander, P.; Haase, W.; Reiländer, H., 1996:
Pharmacological and biochemical characterization of the mouse 5HT5A serotonin receptor heterologously produced in the yeast Saccharomyces cerevisiae

Rodriguez, C.O.; Legha, J.K.; Estey, E.; Keating, M.J.; Gandhi, V., 1998:
Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphatein primary human leukemia cells

Hachisu, M.; Ichimaru, Y., 2000:
Pharmacological and clinical aspects of fluvoxamine (Depromel), the first selective serotonin reuptake inhibitor approved for clinical use employed in Japan

Klein-Galczinsky, C., 1999:
Pharmacological and clinical effectiveness of a fixed phytogenic combination trembling poplar (Populus tremula), true goldenrod (Solidago virgaurea) and ash (Fraxinus excelsior) in mild to moderate rheumatic complaints

Rosito, G.A.; Silva, O.B.; Ribeiro, J.P., 2001:
Pharmacological and clinical evidence for the use of low-molecular-weight heparins in acute coronary syndromes

Smalling, R.W., 1998:
Pharmacological and clinical impact of the unique molecular structure of a new plasminogen activator

Oyabe, A.; Sano, H., 2002:
Pharmacological and clinical profile of nifekalant (shinbit injection), a class III antiarrhythmic drug

Ohta, T.; Komatsu, S.; Tokutake, N., 2003:
Pharmacological and clinical properties of alendronate sodium hydrate

Astrup, A.; Breum, L.; Toubro, S., 1995:
Pharmacological and clinical studies of ephedrine and other thermogenic agonists

Loran, O.B.; Pushkar', D.Iu.; Avetisian, M.M.; Rasner, P.I., 2001:
Pharmacological and cost effectiveness bases of the use of categel and categel S [correction of F] in urological practice

Brugada, J.; Brugada, R.; Brugada, P., 2001:
Pharmacological and device approach to therapy of inherited cardiac diseases associated with cardiac arrhythmias and sudden death

Mizushige, K.; Ueda, T.; Matsuo, H., 1998:
Pharmacological and exercise stress echocardiography

Moguilevsky, N.; Varsalona, F.; Guillaume, J.P.; Noyer, M.; Gillard, M.; Daliers, J.; Henichart, J.P.; Bollen, A., 1995:
Pharmacological and functional characterisation of the wild-type and site-directed mutants of the human H1 histamine receptor stably expressed in CHO cells

Schousboe, A., 2000:
Pharmacological and functional characterization of astrocytic GABA transport: a short review

Yang, C.M.; Tsai, Y.J.; Pan, S.L.; Wu, W.B.; Wang, C.C.; Lee, Y.S.; Lin, C.C.; Huang, S.C.; Chiu, C.T., 2000:
Pharmacological and functional characterization of bradykinin receptors in rat cultured vascular smooth muscle cells

Karmakar, S.; Dasgupta, S.C.; Gomes, A., 2003:
Pharmacological and haematological study of shol fish (Channa striatus) skin extract on experimental animal

Bruno, S.; DeLaurentis, N.; Milillo, M.A.; Tantillo, G.; Perillo, A., 1996:
Pharmacological and histopathological aspects of 1-methyl-4-phenyl-4-hydroxy-piperidine (MPIP)

Wang, Z.Y.; Herman, J.K.; O'Halloran, K.D.; Keith, I.M.; Bisgard, G.E., 2001:
Pharmacological and immunochemical evidence of the dopamine D3 receptor in the goat carotid body

Zanardo, R.C.; Costa, E.; Ferreira, H.H.; Antunes, E.; Martins, A.R.; Murad, F.; D.N.cci, G., 1998:
Pharmacological and immunohistochemical evidence for a functional nitric oxide synthase system in rat peritoneal eosinophils

Yamamoto, M.; Nakao, M.; Mizutani, Y.; Takahashi, T.; Watanabe, K.; Arai, H.; Sasaki, N., 1994:
Pharmacological and model-based interpretation of neuronal dynamics transitions during sleep-waking cycle

González, A.A.; Farré, R.; Monés, J.; Capellà, G.; Clavé, P., 2000:
Pharmacological and molecular characterization of muscular cholecystokinin receptors in the human lower oesophageal sphincter

Hammond, D.L.; Kaneko, M.; Mestre, C., 1999:
Pharmacological and neuroanatomical studies of the antinociceptive effects of intrathecally administered gabapentin

Egan, M.F.; Hurd, Y.; Ferguson, J.; Bachus, S.E.; Hamid, E.H.; Hyde, T.M., 1996:
Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol

Piotrowski, P., 2002:
Pharmacological and non-pharmacological interventions improve food intake in cancer related anorexia and cachexia

Lean, M.E.; Burns, J., 2001:
Pharmacological and nuritional attempts to correct oxidative stress

Sugrue, M.F., 1999:
Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors

Huang, J.Q.; Hunt, R.H., 2001:
Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician

Matsunaga, T., 2001:
Pharmacological and pharmacokinetic properties of azithromycin (Zithromac), a novel 15-membered ring macrolide antibacterial agent

Ueda, N.; Nomura, Y.; Muta, Y.; Matsuzaki, Y.; Hayashibe, M.; Ino, Y.; Suzuki, S.; Kurumi, M., 1998:
Pharmacological and pharmacokinetic studies of the newly synthesized thiazolidinedione derivative 5-(4-(1-phenyl-1-cyclopropanecarbonylamino)benzyl)-thiazolidine-2 ,4-dio ne

Wooltorton, J.R.; Moss, S.J.; Smart, T.G., 1998:
Pharmacological and physiological characterization of murine homomeric beta3 GABA(A) receptors

Kanazawa, I.; Fukuda, Y., 1996:
Pharmacological and physiopathological study of the corpus striatum

Sparg, S.G.; van Staden, J.; Jäger, A.K., 2002:
Pharmacological and phytochemical screening of two Hyacinthaceae species: Scilla natalensis and Ledebouria ovatifolia

Perry, S.W., 1987:
Pharmacological and psychological research on AIDS: some ethical considerations

Gerson, S.; Belin, T.R.; Kaufman, A.; Mintz, J.; Jarvik, L., 1999:
Pharmacological and psychological treatments for depressed older patients: a meta-analysis and overview of recent findings

D.L.o, D.; Scocco, P.; Meneghel, G., 2001:
Pharmacological and psychotherapeutic treatment of personality disorders in the elderly

Abi-Dargham, A.; Laruelle, M.; Wong, D.T.; Robertson, D.W.; Weinberger, D.R.; Kleinman, J.E., 1993:
Pharmacological and regional characterization of [3H]LY278584 binding sites in human brain

Gintautas, J.; Angus, L.D.; Dutt, P.E.; Abadir, A.R., 1994:
Pharmacological and surgical management of pediatric renal injuries

Adler, C.H.; Kumar, R., 2001:
Pharmacological and surgical options for the treatment of cervical dystonia

Spaulding, C.; Cabanes, L.; Weber, S., 1997:
Pharmacological and therapeutic basis for combined administration of beta blockers and calcium channel blockers in the treatment of stable chronic angina

Burns, S.M.; Lawson, C., 1999 :
Pharmacological and ventilatory management of acute asthma exacerbations

Gambero, A.; Gomes, J.C., 1999:
Pharmacological antagonism of Anchietia salutaris extracts on the contraction induced by prostaglandin D2 and U46619 in guinea-pig lung parenchymal strips

Chang, F.C.T.; Hoffman, B.E.; DeBus, S., 2002:
Pharmacological antagonism of lethal effects induced by O-isobutyl S-[2-(diethylamino)ethyl]methylphosphonothioate